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Stromal derived growth factor alpha (SDF-1α) induces the differentiation of bone 
marrow progenitor cells (BMCs) into pericytes by regulating platelet derived growth 
factor B (PDGF-B) transcription  
 
Randala Hamdan, B.S. 
Supervisory Professor, Eugenie S. Kleinerman, M.D. 
We previously demonstrated that bone marrow cells (BMCs) migrate to TC71 and A4573 
Ewing’s sarcoma tumors where they can differentiate into endothelial cells (ECs) and 
pericytes and, participate in the tumor vascular development. This process of neo-
vascularization, known as vasculogenesis, is essential for Ewing’s sarcoma growth with the 
soluble vascular endothelial growth factor, VEGF165, being the chemotactic factor for BMC 
migration to the tumor site. Inhibiting VEGF165 in TC71 tumors (TC/siVEGF7-1) inhibited 
BMC infiltration to the tumor site and tumor growth. Introducing the stromal-derived 
growth factor (SDF-1α) into the TC/siVEGF7-1 tumors partially restored vasculogenesis 
with infiltration of BMCs to a perivascular area where they differentiated into pericytes and 
rescued tumor growth. RNA collected from the SDF-1α-treated TC/siVEGF7-1 tumors also 
revealed an increase in platelet-derived growth factor B (PDGF-B) mRNA levels. PDGF-B 
expression is elevated in several cancer types and the role of PDGF-B and its receptor, 
PDGFR-β, has been extensively described in the process of pericyte maturation. However, 
the mechanisms by which PDGF-B expression is up-regulated during vascular remodeling 
and the process by which BMCs differentiate into pericytes during tumor vasculogenesis 
remain areas of investigation. In this study, we are the first to demonstrate that SDF-1α 
regulates the expression of PDGF-B via a transcriptional mechanism which involves 
binding of the ELK-1 transcription factor to the pdgf-b promoter. We are also first to 
validate the critical role of the SDF-1α/PDGF-B pathway in the differentiation of BMCs 
 vii 
into pericytes both in vitro and in vivo. SDF-1α up-regulated PDGF-B expression in both 
TC/siVEGF7-1 and HEK293 cells. In contrast, down-regulating SDF-1α, down-regulated 
PDGF-B. We cloned the 2 kb pdgf-b promoter fragment into the pGL3 reporter vector and 
showed that SDF-1α induced pdgf-b promoter activity. We used chromatin 
immunoprecipitation (ChIP) and demonstrated that the ELK-1 transcription factor bound to 
the pdgf-b promoter in response to SDF-1α stimulation in both TC/siVEGF7-1 and HEK293 
cells. We collected BMCs from the hind femurs of mice and cultured the cells in medium 
containing SDF-1α and PDGF-B and found that PDGFR-β+ BMCs differentiated into NG2 
and desmin positive pericytes in vitro. In contrast, inhibiting SDF-1α and PDGF-B 
abolished this differentiation process. In vivo, we injected TC71 or A4573 tumor-bearing 
mice with the SDF-1α antagonist, AMD3100 and found that inhibiting SDF-1α signaling in 
the tumor microenvironment decreased the tumor microvessel density, decreased the tumor 
blood vessel perfusion and, increased tumor cell apoptosis. We then analyzed the effect of 
AMD3100 on vasculogenesis of Ewing’s sarcoma and found that BMCs migrated to the 
tumor site where they differentiated into ECs but, they did not form thick perivascular 
layers of NG2 and desmin positive pericytes. Finally, we stained the AMD3100-treated 
tumors for PDGF-B and showed that inhibiting SDF-1α signaling also inhibited PDGF-B 
expression. All together, these findings demonstrated that the SDF-1α/PDGF-B pathway 
plays a critical role in the formation of BM-derived pericytes during vasculogenesis of 
Ewing’s sarcoma tumors.  
 
 
 
 
 
 
 
 viii 
Table of Contents 
 
Approval 
Signatures………………………………………………………………………………....…i  
Title Page…..…………………………………………………………………………..……ii 
Dedications……………………………………………………………………………..…..iii 
Acknowledgements…..………………………………………………………………….....iv 
Abstract…..………………………………………………………………………….……..vi 
Table of Contents…..………………………………………………………………….…viii  
List of Figures…..……………………………………………………………………….xiii 
List of Tables…………………………………………………………………………...xvi 
CHAPTER 1. Introduction……………………………………………………………...1 
Ewing’s Sarcoma…..……………………………………………………………………….2  
Blood vessel development by vasculogenesis……………………………………………...3 
Vasculogenesis in Ewing’s sarcoma…………………………………………………….....4 
 Bone marrow transplant model……………………………………………………...5 
 Vasculogenesis is essential for Ewing’s sarcoma…………………………………...6 
 The role of vascular endothelial growth factor (VEGF165) in vasculogenesis……....6 
Stromal-derived growth factor (SDF-1α) and BMC chemotaxis…………………..……7 
SDF-1α partially rescues vasculogenesis in VEGF165-inhibited TC/siVEGF7-1      
Ewing’s sarcoma tumors………………………………….………………………...8 
Pericytes/vascular smooth muscle cells (vSMCs)……………………………….………10 
 The role of pericytes in tumor vessel development…………………..…………….11 
 ix
Platelet derived growth factor B (PDGF-B) is critical for pericyte maturation…..…..13 
 The role of PDGF-B in pericyte maturation during tumor growth…………….…..13 
 A link between pericyte maturation and PDGF-B in Ewing’s sarcoma……….…..14 
The ELK-1 transcription factor…………………..……………………………………...14 
 SDF-1α activates ELK-1………………………….………………………………..15 
Hypothesis………………………………………………………….…………………...…16 
CHAPTER 2. SDF-1α regulates PDGF-B expression in vitro and in vivo………..……18 
Rationale……………………………………………………………………..…………….19 
Results……………………………………………………………………………………...21 
 SDF-1α up-regulates PDGF-B mRNA levels in vitro…………………………..….21 
 SDF-1α up-regulates PDGF-B protein levels in vitro and in vivo………………....23 
 Down-regulating SDF-1α down-regulates PDGF-B expression…………………...26 
Summary………………………………………………………………………..…………29 
CHAPTER 3. SDF-1α regulates PDGF-B via a transcriptional mechanism which 
involves binding of the ELK-1 transcription factor to the pdgf-b promoter…………..30 
Rationale………………………………………………………………………...…………31 
Results…………………………………………………...…………………………………33 
 SDF-1α regulates PDGF-B expression via transcription……………………..........33 
 SDF-1α induces binding of the ELK-1 transcription factor to the pdgf-b promoter.35  
 The ELK-1 transcription factor is phosphorylated at serine 383 in response to SDF- 
            1α in HEK293 ChIP samples…………………………………………………..…...40 
Summary…………………………………………………………………………………..42 
 x
CHAPTER 4. The SDF-1α/PDGF-B pathway induces the differentiation of bone 
marrow progenitor cells (BMCs) into pericytes in vitro………………………….…….44 
Rationale……………………………………………..…………………………………….45 
Results…………………………………………………………………………..………….47 
 Fresh BMCs express PDGFR-β but do not express NG2 and desmin mature pericyte   
            markers…………………………………………………………..…………………47 
 BMCs differentiate into pericytes when cultured in conditioned medium from  
            10T1/2 cells……………..………………………………………………………….49 
 BMCs do not differentiate into pericytes when cultured in 10T1/2-sh-SDF-1 
            conditioned medium compared to 10T1/2-sh-control medium………………….....51 
Summary……………………………………………………………………………….….53 
CHAPTER 5. The SDF-1α antagonist AMD 3100 negatively impacts tumor vessel 
development in the Ewing’s sarcoma tumor model…………………….………………55 
Rationale………………………………………………………………………………..….56 
 The SDF-1α antagonist AMD 3100………………………………….…………….56 
 AMD 3100 and Ewing’s sarcoma……………….…………………………………57 
Results………………………..…………………………………………………………….58 
AMD3100 leads to smaller vessels with smaller lumens in both TC71 and A4573 
Ewing’s sarcoma tumors……………………………………………..…………….58 
 AMD 3100 decreases the overall microvessel density in both TC71 and A4573    
            Ewing’s sarcoma tumors.………………………………………….……………….60 
            AMD3100 decreases the amount of perfused vessels in both TC71 and A4573  
            Ewing’s sarcoma tumors…………………………………………………………...62 
 xi
            AMD3100 increases apoptosis in both TC71 and A4573 Ewing’s sarcoma      
            tumors........................................................................................................................64 
Summary………………………………………………………….……………………….66 
CHAPTER 6. The SDF-1α/PDGF-B pathway plays a critical role in the differentiation 
of BMCs into pericytes in Ewing’s sarcoma tumors…………………….……………...68 
Rationale……………………………………………..…………………………………….69 
Results………………………………………………………………..…………………….72 
 BMCs migrate to AMD 3100-treated tumors where they predominantly    
            differentiate into ECs but do not form thick perivascular layers……..…………….72 
 AMD 3100 decreases the differentiation of BMCs into NG2 and desmin (+)    
            pericytes in TC71 and A4573 tumors……………………………...……………….74 
 AMD 3100 decreases the total NG2 and desmin+ pericyte content in TC71 and  
            A4573 Ewing’s tumors……......……………………………………………………76 
 AMD3100 decreases PDGF-B expression in Ewing’s sarcoma tumors……….…..78 
Summary………………….……………………………………………………………….79 
CHAPTER 7. AMD 3100 does not display a therapeutic effect in the treatment of 
primary Ewing’s sarcoma tumors………………………………………….……………80 
Rationale……………………..…………………………………………………………….81 
Results…………………………………………………………..………………………….83 
 AMD 3100 treatment leads to a trend towards decreased overall tumor volume in  
            both TC71 and A4573 Ewing’s tumors……………………..……………………...83  
 AMD 3100 did not increase the survival of TC71 or A4573-tumor bearing mice...85  
Summary…………………………………………………………………………………..87 
 xii
CHAPTER 8. Appendix   ……………………………………………………………..….89 
 The pdgf-b/pGL3 vector is functional……………………………………..……….90  
 SDF-1α induces the phosphorylation of the ELK-1 transcription factor at serine 383   
            with a peak at 30 minutes in TC/siVEGF7-1 cells…………………………..………91 
CHAPTER 9. Discussion and future directions……………………...………………….93 
Discussion………………..………………………………………………………………...94 
 SDF-1α regulates PDGF-B by a transcriptional mechanism which involves the  
            ELK-1 transcription factor……………………………..……………………….….94 
 The SDF-1α/PDGF-B pathway plays a critical role in BM-derived pericyte  
            differentiation during vasculogenesis of Ewing’s sarcoma……………………...…97 
 AMD 3100 as anti-vascular therapeutic agent………………………..…………..103 
 Conclusion………………………………………………………………...………108 
Future directions………..……………………………………………………………….110 
 Investigate the therapeutic effect of AMD 3100 on Ewing’s sarcoma metastasis..110 
 Investigate the possibility of a BM pre-metastatic niche in the lungs which could  
            function to support Ewing’s sarcoma metastasis post treatment with AMD3100..111  
 Investigate the therapeutic effect of AMD 3100 in combination with DC101 anti- 
            VEGFR-2 in Ewing’s sarcoma………………………………………………..…..113 
CHAPTER 10. Materials and Methods……………………………..………………….115 
Bibliography……………………………………………………………………..……….129 
Vita…………………………………………………………..……………………………141 
 
 
 xiii 
List of figures 
 
Figure 1. Bone marrow transplant model……………………..………………………….5 
Figure 2. Hypothesis………………..……………………………………………………..17 
Figure 3. SDF-1α up-regulates PDGF-B mRNA levels in vttro ……………..…………22 
Figure 4. SDF-1α up-regulates PDGF-B protein levels………………………..………..25 
Figure 5. Down-regulating SDF-1α decreases PDGF-B mRNA levels………….……..28 
Figure 6. SDF-1α regulates PDGF-B expression via transcription…………..………...34 
Figure 7.  The ELK-1 transcription factor binds to pdgf-b promoter in response to  
SDF-1α……………………………………..……………………………………………....39 
Figure 8. ELK-1 is phosphorylated at S383 in response to SDF-1α in HEK293 ChIP 
samples……………………………………..………………………………………………41 
Figure 9. Freshly isolated BMCs express the early pericyte marker PDGFR-β but do 
not express desmin and NG2 mature pericyte markers…………………………..…….48 
Figure 10. 10T1/2 conditioned medium induces BMCs to differentiate into pericytes as 
defined by morphology and the expression of NG2 and desmin…………………..…...50 
Figure 11. BMCs cultured in 10T1/2-sh-SDF-1 conditioned medium do not 
differentiate into pericytes as defined by morphology and expression of NG2 and 
desmin………………………………………………………………………………….…..52 
Figure 12. Tumor vessels are smaller with smaller lumens in response to AMD 3100 in 
both TC71 and A4573 Ewing’s sarcoma tumors…………………………………..…....59 
Figure 13. The total microvessel density is decreased in response to AMD 3100 in both 
TC71 and A4573 Ewing’s sarcoma tumors…………………………………...…………61 
 xiv
Figure 14. AMD 3100 decreased the total amount of perfused vessels in both TC71 
and A4573 Ewing’s tumors……………………………...………………………………..63 
Figure 15. AMD 3100 increases apoptosis in both TC71 and A4573 Ewing’s 
tumors...................................................................................................................................65 
Figure 16. BMCs migrate to both TC71 and A4573 AMD 3100-treated tumors where 
they differentiate into ECs but do not form thick perivascular layers………………...73 
Figure 17. AMD 3100 decreases the differentiation of BMCs into desmin and NG2 
positive pericytes in both TC71 and A4573 Ewing’s tumors……………..…………….75 
Figure 18. AMD 3100 decreases the total amount of desmin and NG2 pericytes in both 
TC71 and A4573 Ewing’s tumors………………….………………………………….…77 
Figure 19. AMD 3100 decreases PDGF-B expression in both TC71 and A4573 Ewing’s  
tumors……………………………………..………………………………………..……...78 
Figure 20. AMD 3100 does not statistically decrease the final TC71 and A4573 tumor 
volumes compared to PBS…………………………………….………………………….84 
Figure 21. AMD 3100 did not increase the survival of TC71 and A4573 tumor-bearing 
mice………………………………….……………………………………………………..86 
Figure 22. Summary…………………………………………………………..…………107 
Figure A1. The pdgf-b/pGL3 construct is functional…………………………...….…...90 
Figure A2. The ELK-1 transcription factor is phosphorylayed at S383 in response to 
SDF-1α stimulation in TC/siVEGF7-1 cells…………………..…………………………..92 
 
 
 
 xv
List of tables 
 
Table 1. Forward and reverse primers……....…………………………….....…….......121 
Table 2. Immunohistochemistry primary and secondary antibodies...…..…………..126 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                             
 
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1. 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                             
 
2
Ewing’s sarcoma  
Ewing’s sarcoma is a member of the Ewing’s sarcoma family of tumors (ESFT), an 
aggressive form of childhood cancer. While bone tumors account for about 5% of all 
childhood and adolescent cancers, Ewing’s sarcoma is the second most common pediatric 
bone tumor after osteosarcoma (1, 2). Ewing’s sarcoma tumors are more prevalent in males 
than females with a peak incidence in young adults around the age of 15.  Although the 
tumors most commonly occur in bone, especially the pelvis, the long bones and the bones 
of the chest wall; the cancer can arise in any bone or soft tissue (2). ESFT display an 
aggressive behavior with a tendency towards recurrence following resection and are highly 
metastatic to the lungs (50%), bone (25%) and bone marrow (20%) (1-3).  
Most patients with Ewing’s sarcoma present with tumor-related symptoms such as 
pain and tumor mass and are diagnosed using biopsy, imaging and molecular DNA testing 
(1). In more than 85% of cases, patients with Ewing’s sarcoma are characterized with the 
translocation and fusion of the EWSR1 gene to the ETS family FLI1 gene t(11;22)(q24;q12) 
resulting in the formation of the EWS/FLI1 protein (4). Additional translocations between 
the EWS gene and members of the ETS family of transcription factors have also been 
reported (EWS/ERG fusion) (2). While the role of the EWS/FLI1 gene has been established 
as a prognostic factor, the many implications of this fusion in the treatment plan and patient 
clinical outcome remains an area of investigation (4).  
The current therapy regimen for patients with Ewing’s sarcoma includes surgery, 
radiation therapy, and chemotherapy with surgery being the preferred method of local  
control (2). In cases where surgery is not possible due to the site or size of the tumor mass, 
then radiation therapy becomes the preferred treatment regimen (4). Most patients with 
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Ewing’s sarcoma present with micrometastasis at the time of diagnosis or after the first 
round of therapy; therefore, despite a survival of about 65 – 75% in non-metastatic Ewing’s 
sarcoma patients, patients with recurrent disease or metastasis at time of diagnosis still have 
only about 20 – 25% overall survival (5). The need for improvement in therapy is evident. 
Therefore, it becomes important for us to better understand the tumor biology and the role 
of the tumor microenvironment in supporting tumor growth in order to devise new 
therapeutic approaches.  
Blood vessel development by vasculogenesis  
Solid tumors are highly angiogenic; they depend on a vascular network for their 
growth, invasion and metastasis (6). While angiogenesis is the process by which new blood 
vessels form from pre-existing capillaries by vessel sprouting or endothelial budding (7), 
vasculogenesis is the process involving the migration and homing of bone marrow-
progenitor cells (BMCs) from the bone marrow (BM) to the sites of neo-vascularization 
where they can participate in the blood vessel development (8, 9).  Vasculogenesis was 
thought to be limited to early embryogenesis and not occur in adults. However, recent 
studies have shown that both angiogenesis and vasculogenesis contribute to embryonic 
development, adult wound healing and, tumor growth (8-11).  
During embryonic development, vasculogenesis involves growth and fusion of 
multiple blood islands that ultimately give rise to the yolk sac capillary network. After the 
onset of blood circulation, this capillary network differentiates into an arteriovenous 
vascular system. While hematopoietic stem cells (HSCs) are situated in the center of the 
blood island and are destined to generate hematopoietic cells, endothelial progenitor cells 
(EPCs) or angioblasts are located at the periphery of the blood islands (9, 12).  
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In 1997, Asahara and his colleagues first reported the isolation of EPCs from human 
peripheral blood on the basis of cell surface expression of CD34 and other endothelial 
markers (12). In response to certain cytokines or tissue ischemia, BM-derived EPCs are 
increased in the systemic circulation. These cells home to, and incorporate into sites of neo-
vascularisation (9, 12, 13).  
The first evidence of BMC migration and incorporation into sites of tumor neo-
angiogenesis was provided by Rafii and his colleagues in 2001. They showed that tumor 
did not form in the Id- (inhibitor of differentiation)-mutant mice.  These mice cannot 
support neo-angiogenesis due to impaired vascular endothelial growth factor (VEGF) -
driven mobilization of VEGFR2+ and impaired proliferation and incorporation of 
VEGFR1+ EPCs. However, transplantation of the Id-mutant mice with wildtype BMCs or 
VEGF-mobilized stem cells restored neo-angiogenesis and tumor growth (14). These 
findings demonstrated that vasculogenesis can be essential to tumor neo-vascularization.  
Vasculogenesis in Ewing’s sarcoma 
Ewing’s sarcoma tumors rely on an extensive vascular network for survival and 
growth (6, 15). We investigated the role of vasculogenesis in Ewing’s sarcoma tumors and 
found that about 10% of the tumor vessels possess at least one BM-derived endothelial cell. 
CD34+ BM progenitor cells were shown to migrate from the BM to the tumor site and 
participate in the process of tumor neo-vascularization (10, 16). In order to further 
investigate the role of vasculogenesis in the Ewing’s sarcoma tumor models, we needed a 
more efficient way of tracking BMC migration and infiltration into the tumor site. We 
therefore designed a bone marrow transplant model (BMT) in which GFP+ transgenic mice 
were used as donor mice, and nude mice were used as recipients.  
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GFP (+) transgenic 
mice (Donors)
1) Nude mice undergo      
whole body lethal   
irradiation
3) 4 weeks:
Time for 
engraftment
4) Subcutaneous injection of TC71 
or A4573 Ewing’s sarcoma cells
5) 2- 3 weeks:
Time for tumors to 
establish
6) Mice are sacrificed
Tumors are harvested 
Tumor sections are analyzed by IHC
Nude mice (Recipients)
2) Bone marrow is 
reconstituted from GFP(+) 
transgenic donors
Bone marrow transplant model 
Nude mice (recipients) were submitted to whole body lethal irradiation to eradicate 
the existing BM constituents and then rescued by an intravenous injection of GFP+ BMCs 
collected from the donor transgenic mice. Engraftment was confirmed one month later by 
flow cytometry then, the mice received subcutaneous injections of the Ewing’s sarcoma 
tumor cells. The Tumors were resected 2-3 weeks after tumor cell injection and analyzed by 
immunohistochemistry staining (IHC). If the mice or tumors were to receive any form of 
treatment, we administered the treatment once the tumors were palpable. 
 
Figure 1. Bone marrow transplant model. 
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Vasculogenesis is essential for Ewing’s sarcoma 
To investigate whether BMCs and vasculogenesis was an essential process for 
Ewing’s sarcoma tumor growth, we used the Mekk3-deficient conditional knockout mice. 
Mekk3- BM cells cannot form vessels and therefore will not contribute to the tumor vessel 
development. Transplanting Mekk3-deficient BMCs into mice resulted in decreased tumor 
vessel density and tumor growth (17).  
We also analyzed the different BMC sub-populations that support vasculogenesis of 
Ewing’s sarcoma. We found that the human CD34+/CD45+ and CD34+/CD38- cells, 
synonymous to the murine VEGFR2+ and Sca1+/Gr1+ cells, co-localized with the tumor 
vascular network, and differentiated into CD31+ or human vascular endothelial cadherin+ 
endothelial cells. These cell populations were also found to be in close proximity to the 
vessel wall, differentiating into desmin and alpha-smooth muscle actin (α-SMA) positive 
pericytes. The human CD34-/CD45+ population synonymous to the mouse Sca1-/Gr1+ cells, 
migrated predominantly to sites in the tumor paranchema outside of the tumor vasculature 
and differentiated into monocytes/macrophages expressing F4/80 or CD14 (18). All 
together, these findings demonstrated that vasculogenesis plays a critical role in the 
formation of Ewing’s sarcoma tumor vessels. 
The role of the vascular endothelial growth factor (VEGF165) in vasculogenesis  
We next investigated the mechanism by which BMCs migrated to the tumor site. 
Vascular endothelial growth factor (VEGF) is a very well characterized cytokine and its 
role in angiogenesis and tumor vessel remodeling has been extensively described (19-21). 
We analyzed several Ewing’s sarcoma cell lines and patient samples for the expression of 
VEGF. We found that Ewing's sarcoma over-express VEGF and that there was a shift in 
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isoforms from the extracellular matrix–bound VEGF189 isoform, to the smaller and more 
soluble VEGF165 isoform (16, 22). Further studies confirmed that VEGF165 stimulated BMC 
migration to the tumor and the tumor vessels (10, 16, 23).  
To characterize the role of VEGF165 in vasculogenesis of Ewing’s sarcoma, we used 
an si-RNA specific for VEGF165 and generated the TC/siVEGF7-1 cell line with decreased 
VEG165. Using our BMT model (Figure 1), we found that TC/siVEGF7-1 tumors were 
smaller with decreased infiltration of BMCs into the tumor site and decreased 
vasculogenesis (24). Introducing VEGF189 into TC/siVEGF7-1 tumors did not rescue tumor 
growth or increase the tumor vessel density (25). These findings demonstrated that 
VEGF165 was the chemotactic stimulus for BMC migration to the tumor site. 
Stromal derived growth factor (SDF-1α) and BMC chemotaxis 
Chemokines are small highly charged molecules, secreted or membrane-bound, 
ranging from 6-14 kDa in size (26) . They are involved in a variety of immune reactions 
such as infection, inflammation and tissue repair (27). To date, there are more than fifty 
different chemokines that have been identified along with over twenty chemokine receptors 
that have been cloned (28). Chemokines are classified into four major classes based on the 
arrangement of the conserved cysteine (C) residues near the NH2-terminus of the mature 
protein; the CXC or α-chemokine, the CC or β-chemokines, the C or γ-chemokines and, the 
CXXXC or δ-chemokines (29). Chemokines bind to G-protein-coupled seven 
transmembrane receptors present on the surface of target cells; they can bind to multiple 
receptors and, the same receptor can bind to more than one chemokine (28).  
The α-chemokine, stromal derived growth factor (SDF-1) has two main isoforms 
SDF-1α and β, with SDF-1α being the predominant isoform (26). SDF-1α or CXCL12 
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binds specifically to the G-protein coupled receptor CXCR4 which can only bind to SDF-
1α (28).  Recent studies suggested that SDF-1α can also bind to the orphan receptor RDC1 
also known as CXCR7; however, the signaling properties of this receptor remain unclear 
(30). The SDF-1α chemokine is constitutively expressed. It is produced by multiple BM-
stromal cell types and by the epithelial cells in several organs such as the liver, heart, lung, 
brain and bone marrow. Its receptor, CXCR4, is also expressed on the surface of many cell 
types including hematopoietic, endothelial, stromal and neuronal cells (31). SDF-
1α/CXCR4 knockout studies in mice are embryonic lethal and no SDF-1α/CXCR4 
deficiencies have been described in humans (28).  In contrast, patients with a mutation 
leading to the activation of CXCR4 suffer from warts, hypogammaglobulinemia, 
immunodeficiency and myelokathesis (WHIM) syndrome (32).  
The SDF-1α/CXCR4 axis has been implicated in several biological processes. It is 
involved in homeostasis and functions to regulate hematopoietic cell trafficking and 
secondary lymphoid tissue architecture (31, 33). In adult life, SDF-1α plays an important 
role in the retention and homing of BM progenitor cells to the BM (28, 34). SDF-1α 
provides a chemotactic gradient for CXCR4 (+) BM progenitor cells and its implication in 
embryonic and adult postischemia and tumor angiogenesis has been extensively described 
(35-37).   
SDF-1α partially rescues vasculogenesis in VEGF165-inhibited TC/siVEGF7-1 Ewing’s 
sarcoma tumors  
The expression of various angiogenic growth factors such as VEGF and b-FGF is 
enhanced during tumor development and play a critical role in tumor blood vessel 
development (35). The SDF-1α serum levels have been shown to become elevated in 
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response to ischemia and tumor growth and induce the mobilization of mature and 
immature hematopoietic progenitor and stem cells into the peripheral blood (38). 
Furthermore, a study by Gabriele Bergers and colleagues in 2008 demonstrated that HIF-
1α, a direct effector of hypoxia, induced the recruitment of BM-progenitor myeloid cells, as 
well as endothelial and pericyte progenitor cells to sites of neo-vascularization in 
glioblastoma tumors through increases in SDF-1α (39).  
As previously described, findings from our lab demonstrated that vasculogenesis 
plays a critical role in Ewing’s sarcoma growth and that VEGF165 is the chemotactic factor 
for BMC migration to the site of neo-vascularization (10, 16). Inhibiting VEGF165 in TC71 
tumors (TC/siVEGF7-1), decreased infiltration of BMCs into the tumor site, decreased 
vasculogenesis and inhibited tumor growth. We analyzed SDF-1α expression in 
TC/siVEGF7-1 tumors and found that inhibiting VEGF165 also decreased SDF-1α (24, 40).  
Given the role of SDF-1α as a chemotactic factor for BM-progenitor cells, we 
introduced SDF-1α into the TC/siVEGF7-1 tumors using an adenoviral vector containing the 
SDF-1α gene (Ad-SDF-1α) to determine if BMCs could rescue tumor growth in the 
absence of VEGF165. We found that SDF-1α restored the infiltration of BMCs into the 
tumor site, increased tumor vessel density and, enhanced the growth of TC/siVEGF7-1 
tumors (31, 40, 41). SDF-1α, while having no effect on VEGF165 expression, induced the 
infiltration of BMCs predominantly to the perivascular area. Immunohistochemistry 
analysis (IHC) demonstrated that the majority of these BMCs differentiated into pericytes 
or vascular smooth muscle cells (vSMCs) (40). These findings once again emphasized the 
critical role of BMCs and the process of vasculogenesis in Ewing’s sarcoma tumor growth. 
Furthermore, our data suggested a correlation between SDF-1α and BM-derived pericyte 
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maturation and indicated a critical role for these BM-derived pericytes in supporting tumor 
neo-vascular development and tumor growth.  
Pericytes/vascular smooth muscle cells (vSMCs) 
Small blood vessels such as capillaries have two types of cell layers, the inner lining 
of the vessel wall composed of endothelial cells (EC) and the surrounding perivascular 
layer of cells, referred to as pericytes, vascular smooth muscle cells or mural cells which 
envelop the surface of the vascular tube. Both layers together form the basement membrane 
of microvessels (42). Pericytes were identified over a 100 years ago by Charles Rouget and 
are referred to as vascular smooth muscle cells (vSMCs) because of their contractile 
filaments (43). Pericytes possess a cell body with a prominent nucleus, a small amount of 
cytoplasm, and long processes that embrace several endothelial cells at once or extend to 
more than one capillary. Pericytes communicate with endothelial cells by direct physical 
contact and/or through paracrine signaling pathways (42).  
Pericytes/vSMCs vary in location and have diverse characteristics and functions 
(42). They regulate vascular diameter and capillary blood flow by vasoconstriction and 
vasodilatation of the capillary beds. Pericytes are described as multipotent mesenchymal 
cells. They have been shown to be precursors to SMCs capable of becoming adipocytes, 
osteoblasts and phagocytes. Majno and colleagues first demonstrated the role of pericytes 
as phagocytes using electron microscopy. Several other studies since have described the 
importance of pericytes as phagocytes or precursors to macrophages in the brain (43-45). 
Pericytes have also been shown to regulate capillary growth. During wound healing, 
pericytes can either form from pre-existing microvessels or come into contact with ECs that 
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are forming new vessels to exert an inhibitory effect on EC proliferation and regulate vessel 
growth (46).  
Pericytes are derived from mesenchymal stem cells. It remains unclear whether 
pericytes are smooth-muscle cells or cells with smooth-muscle-cell characteristics and 
whether these cells even have a distinct progenitor. Therefore, it is very common for 
pericytes to be referred to as vascular smooth muscle cells. Defining a pericyte remains a 
challenge; no general pan-pericyte molecular marker has yet been found. Currently, a few 
molecular markers, although not exclusive to pericytes, have been used for the 
identification of these cells. Depending on the tissue and developmental or angiogenic state 
of a blood vessel, the expression pattern of pericyte markers can vary. The most commonly 
used markers are desmin and alpha smooth muscle actin α-SMA, (contractile filaments), 
regulator of G protein signaling 5 RGS-5, (a GTPase- activating protein), neuron-glial 2 
NG2, (a chondroitin sulfate proteoglycan) and platelet-derived growth factor receptor beta 
PDGFR- β, (a tyrosine kinase receptor) (42).  
The role of pericytes in tumor vessel development 
 Pericytes are found as a single-cell layer or as a solitary cell in close association 
with ECs in the normal vasculature. Both ECs and pericytes are embedded within the 
basement membrane of capillaries where pericytes communicate with ECs or other 
components of the vessel wall to prevent vessel leakage (47). Although the vasculature 
remains quiescent and angiogenesis is an infrequent event in the normal adult, the latter still 
occurs during wound healing or pathological conditions such as diabetic retinopathy and 
tumor growth. However, the difference between normal physiological angiogenesis and 
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pathological angiogenesis lies in the imbalance between the positive and negative 
regulators being expressed in the microenvironment (42).  
During tumor growth, the hypoxic nature of the microenvironment leads to 
vasodilatation, increased vascular permeability and degradation of the vascular basement 
membrane. As a result, the strong and quiescent association between ECs and pericytes is 
destabilized, leakage is increased and tumor vessels appear to be in a constant state of 
remodeling. All together, these dynamic changes lead to vessels that are chaotic, poorly 
organized, tortuous and irregularly shaped (42, 47).  
Tumor vessels as well as pericyte coverage are different depending on the tumor 
type. In general, pericytes within tumors are less abundant and more loosely attached to the 
vessel wall with cytoplasmic structures that can extend deep within the surrounding tumor 
tissue. Until recently, pericytes have been considered abnormal and dysfunctional in tumors 
and therefore, they have been neglected as potential targets for anti-vascular therapy (42). 
However, recent studies have demonstrated that although pericytes are present in a smaller 
number within tumors, targeting pericytes in addition to endothelial cells, resulted in more 
efficient reduction in tumor vasculature than targeting one or the other alone (48).  
The above findings, combined with our observations that SDF-1α gene therapy 
increased the infiltration and differentiation of BMCs into pericytes/vSMCs within 
TC/siVEGF7-1 tumors and subsequently rescued tumor growth, emphasize the importance 
of pericytes as functional cell-components of the tumor vasculature which promote tumor 
growth. These cells therefore may be a potential target for anti-angiogenic therapy.  
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Platelet derived growth factor B (PDGF-B) is critical for pericyte maturation 
Platelet derived growth factor B (PDGF-B) is a member of the PDGF family of 
growth factors which are mitogens for many cells of mesenchymal origin including 
fibroblasts and smooth muscle cells and for some cell populations of neuroectodermal 
origin. The PDGF family is composed of four different polypeptide chains PDGF-A, B, C 
and D. These four polypeptides are encoded by four different genes and can form homo or 
heterodimers. The ligands can bind the two tyrosine kinase receptors, PDGFR-α and 
PDGFR-β. When synthesized and secreted in its homodimer form, PDGF-BB binds to its 
tyrosine kinase receptor, PDGFR-β (49).  
PDGF-B and PDGFR-β are mainly expressed in the developing vasculature, where 
PDGF-B is produced by the endothelial cells and PDGFR-β is expressed by mural cells 
such as pericytes and vSMCs (50). The role of PDGF-B and PDGFR-β in the maturation 
process of pericytes has been extensively described. Blocking the signaling through the 
PDGF-B/PDGFR-β pathway leads to pericyte loss and to endothelial changes followed by 
capillary dilation and rupture (51, 52).   
The role of PDGF-B in pericyte maturation during tumor growth  
The expression of PDGF-B is normally restricted to a limited number of cell types. 
However, many cancers including colorectal cancer, pancreatic cancer, glioma, and 
sarcoma, have been shown to over-express PDGF-B (53, 54). PDGF-B is produced by the 
tumor endothelium and is required for the recruitment of an adequate number of PDGFR-β+ 
pericytes to the tumor vessels and their integration in the vascular wall (55). Studies by 
Rajantie and colleagues reported the detection of BM-derived periendothelial vascular 
mural cells at sites of tumor growth (56). Shortly after, another study by Gabriele Bergers 
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and her group reported the discovery of PDGFR-β-expressing pericyte progenitor cells 
(PPPs) which possess the capacity to differentiate into NG2 (+), desmin (+) and, alpha-
smooth muscle actin (+) pericytes within tumors (57).   
On the other hand, inhibiting PDGFR-β in a mouse model of pancreatic cancer was 
found to deplete tumor pericytes and to induce their detachment from the vascular 
endothelium which resulted in blood vessel hyperdilation and disruption (48). Another 
study using the novel DNA oligonucleotide aptamer (AX102) that selectively binds PDGF-
B showed that inhibiting PDGF-B in Lewis lung carcinomas reduced pericyte coverage and 
tumor vascularity (58).  
A link between pericyte maturation and PDGF-B in Ewing’s sarcoma  
Previous findings from our lab demonstrated that treating VEGF165 inhibited 
Ewing’s sarcoma tumors, TC/siVEGF7-1, with an adenoviral vector containing the SDF-1α 
gene (Ad-SDF-1α) partially restored vasculogenesis with infiltration of BMCs 
predominantly to a perivascular area where they differentiated into pericytes/vSMCs and, 
rescued tumor growth. Given the critical role of PDGF-B in pericyte maturation, RNA was 
extracted from the Ad-SDF-1α treated tumors and analyzed for PDGF-B mRNA 
expression. We found that SDF-1α gene therapy increased PDGF-B mRNA levels in 
TC/siVEGF7-1 tumors (40). These findings suggested a correlation between SDF-1α, 
PDGF-B and BM-derived pericyte differentiation during vasculogenesis of Ewing’s 
sarcoma.   
The ELK-1 transcription factor 
The ELK-1 nuclear transcription factor, a member of the three ternary complex 
factors (TCFs), is one of the 30 or more members of the ETS (E twenty-six) family of 
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transcription factors. All family members share a conserved ~ 85 amino acid DNA-binding 
domain, termed the ETS domain that directs binding to recognition sites containing GGA 
cores. ETS proteins are important mediators of growth-regulating and differentiation 
signaling pathways. Particularly, ETS proteins are effectors of growth factor signaling 
pathways involving RAS/MAPK-dependent signaling (59, 60). Recent evidence suggests 
that ELK-1 is a target of all three classes of MAP kinases ERK, JNK, and p38 MAPK and 
functions as a nuclear transcriptional activator (61). TCFs are involved in several biological 
processes and have been shown to be important in regulating angiogenesis and 
vasculogenesis (62, 63).   
SDF-1α activates ELK-1  
Signaling through the SDF-1α/CXCR4 pathway initiates a cascade of several signal 
transduction pathways linked to transcription and expression through MEK1/2 and ERK1/2. 
ERK can then phosphorylate and activate other cellular proteins as well as translocate to the 
nucleus, phosphorylate and/or, activate transcription factors (33). Binding of SDF-1α to 
CXCR4 induces phosphorylation of the mitogen-activated protein kinases (MAPKs) p44 
ERK-1 and p42 ERK-2, which subsequently initiates the phosphorylation of several down-
stream transcription factors including the nuclear transcription factor ELK-1 (64).  
 Altogether, these findings and observations suggested a link between SDF-1α 
signaling and PDGF-B expression involving the ELK-1 transcription factor and a role for 
the SDF-1α/PDGF-B pathway in BM-derived pericyte differentiation during vasculogenesis 
of Ewing’s sarcoma.  
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Hypothesis 
 
To summarize, we know that  
1) BMCs migrate to VEGF165-inhibted TC/siVEGF7-1 Ewing’s sarcoma tumors in response 
to SDF-1α and differentiate into pericytes/vSMCs  
2) PDGF-B mRNA levels are up-regulated in TC/siVEGF7-1 tumors by SDF-1α with no 
effect on VEGF165 
3) PDGF-B is critical for pericyte maturation 
4) SDF-1α signaling can activate the ELK-1 transcription factor, a member of the ETS 
family of transcription factors  
 
We therefore formulated the following hypothesis that SDF-1α up-regulates the 
expression of PDGF-B via a transcriptional mechanism involving the ELK-1 
transcription factor and in turn, PDGF-B induces the differentiation of bone marrow 
progenitor cells into pericytes during vasculogenesis of Ewing’s sarcoma.  
 
 
 \ 
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Figure 2. Hypothesis. SDF-1α expression is increased in the tumor microenvironment, 
binds to its receptor CXCR4 expressed on either tumor cells or endothelial cells and, 
induces the ERK-1/2 (MAPKs) signaling cascade which activates the ELK-1 transcription 
factor. ELK-1 binds to the PDGF-B promoter and activates the expression and secretion of 
the PDGF-BB protein. PDGF-BB then binds to its PDGFR-β receptor expressed on pericyte 
progenitor cells and induces their differentiation into mature pericytes.  
 
   
                                                                                                                                                                             
 
18
 
 
 
 
 
 
 
 
 
 
 
Chapter 2. 
  
SDF-1α regulates PDGF-B expression in vitro and in vivo 
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Rationale 
 
We previously demonstrated that vasculogenesis is essential for Ewing’s sarcoma 
growth and that VEGF165 is the chemotactic stimulus for bone marrow cell (BMC) 
migration to the tumor site. In fact, inhibiting VEGF165 in TC71 Ewing’s sarcoma tumors 
(TC/siVEGF7-1) inhibited both BMC infiltration into the tumor and tumor growth (16, 24, 
25, 65). However, introducing stromal derived growth factor (SDF-1α) into TC/siVEGF7-1 
tumors using an adenoviral vector containing the SDF-1α gene (Ad-SDF-1α), increased 
infiltration of BMCs to a perivascular area where they differentiated into pericytes/vSMCs 
and, partially rescued tumor growth. RNA collected from the Ad-SDF-1α treated 
TC/siVEGF7-1 tumors also showed an increase in platelet derived growth factor B (PDGF-
B) mRNA levels (40). These observations suggested a correlation between SDF-1α and 
PDGF-B expression. 
PDGF-B is a member of the PDGF family of growth factors which have been 
described as mitogens for cells of mesenchymal origin such as fibroblasts and smooth 
muscle cells (49, 53). PDGF-B binds to its tyrosine kinase receptor PDGFR-β and both 
proteins are mainly expressed in the developing vasculature (51, 66). PDGF-B expression 
has been shown to be up-regulated in tumors, especially the ones established from sarcoma 
and glioma (54, 66). However, the mechanism by which PDGF-B expression is up-
regulated during vascular remodeling remains unclear.  
In this section, we investigated SDF-1α as a regulator of PDGF-B expression. We 
first confirmed up-regulation of PDGF-B protein levels in vivo in the Ad-SDF-1α treated 
TC/siVEGF7-1 tumors by IHC. We then treated both the TC/siVEGF7-1 and HEK293 cells 
                                                                                                                                                                             
 
20
with the recombinant human SDF-1α protein and demonstrated that SDF-1α up-regulated 
PDGF-B mRNA and protein levels in vitro using real time PCR (qPCR) and enzyme linked 
immunosorbent assay (ELISA). By contrast, an shRNA specific for SDF-1α which down- 
regulated SDF-1α mRNA and protein levels also down-regulated PDGF-B. We are the first 
to demonstrate that SDF-1α regulates PDGF-B expression.  
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Results 
 
SDF-1α up-regulates PDGF-B mRNA levels in vitro 
We previously demonstrated that treating VEGF165-inhibited TC/siVEGF7-1 tumors 
with an adenoviral vector containing the SDF-1α gene (Ad-SDF-1α) in order to up-regulate 
SDF-1α expression also up-regulated PDGF-B mRNA levels (40). To confirm that SDF-1α 
up-regulates PDGF-B mRNA in vitro, we used both the TC/siVEGF7-1 and the HEK293 cell 
lines which express low levels of endogenous PDGF-B. The cells were plated in the 
absence of growth factors and supplements for 8 hours and then treated with 100ng/ml of 
either the recombinant human SDF-1α protein or the 9SDF-1α inactive protein for 24 hours. 
Total RNA was collected and the PDGF-B mRNA levels were quantified using q-PCR. 
SDF-1α up-regulated PDGF-B mRNA levels compared to 9SDF-1α in both TC/siVEGF7-1 
and HEK293 cells (Figure 3). 
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Figure 3. SDF-1α up-regulates PDGF-B mRNA levels in vitro. TC/siVEGF7-1 and HEK293 cells 
were plated in the absence of growth factors and supplements for 8 hours and then treated with 
100ng/ml of either SDF-1α or the 9SDF-1α inactive protein for 24 hours. RNA was collected and 
analyzed by q- PCR for the expression of PDGF-B. Bar graph shows pooled data from 3 
independent experiments each performed in triplicate. P < 0.05 was considered significant. SDF-1α 
up-regulates PDGF-B mRNA levels compared to 9SDF-1α.  
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SDF-1α up-regulates PDGF-B protein levels in vitro and in vivo 
To demonstrate that SDF-1α up-regulates PDGF-B protein levels in vitro, 
TC/siVEGF7-1 and HEK293 cells were plated in the absence of growth factors and 
supplements for 8 hours and then treated with 100ng/ml of either the recombinant human 
SDF-1α protein or 9SDF-1α inactive protein for 36 hours. Since the ~27kD PDGF-B 
protein is a secreted protein, the PDGF-B protein levels were quantified using ELISA. 
SDF-1α up-regulated PDGF-B protein levels compared to 9SDF-1α in both TC/siVEGF7-1 
and HEK293 cells (Figure 4A).  
In order to analyze the effect of SDF-1α on PDGF-B protein levels in vivo, PDGF-B 
protein levels were analyzed in the Ad-SDF-1α versus the Ad-control-treated TC/siVEGF7-1 
tumors. Briefly, TC/siVEGF7-1 tumors received 5 intratumoral injections of either Ad-SDF-
1α or Ad-control over a period of 3 weeks. The tumors were then resected, snap frozen in 
OCT and, stored at - 80oC for further analysis by IHC. Tumor sections were obtained and 
analyzed by IHC for PDGF-B protein expression (brown staining). Ad-SDF-1α up-
regulated PDGF-B protein levels compared to Ad-control in TC/siVEGF7-1 tumors (Figure 
4B).  
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Figure 4A. ELISA assay to quantify PDGF-B protein levels  
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Figure 4B. Immunohistochemistry staining to detect PDGF-B protein expression in 
Ad-SDF-1α-treated TC/siVEGF7-1 
 
 
 
Figure 4. SDF-1α up-regulates PDGF-B protein levels. A) ELISA assay for the PDGF-B protein. 
TC/siVEGF7-1 and HEK293 cells were plated in the absence of growth factors and supplements for 
8 hours and then treated with 100ng/ml of either SDF-1α or the 9SDF-1α inactive protein for 36 
hours. The supernatant was collected, concentrated and, the ~ 27kD soluble PDGF-B protein levels 
quantified by ELISA. Bar graph shows pooled data from three independent experiments each 
performed in triplicate. P < 0.05 was considered significant. B) IHC for PDGF-B protein. 
TC/siVEGF7-1 tumors were injected 5 days following tumor cell inoculation with either Ad-SDF-
1α or Ad-control twice weekly for 3 weeks. On day 23, the tumors were resected and tumor sections 
were cut, fixed and analyzed for expression of PDGF-B (brown staining). Ad-SDF-1α up-regulates 
PDGF-B protein levels compared to Ad-control both in vitro and in vivo.  
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Down-regulating SDF-1α down-regulates PDGF-B expression 
To further confirm that SDF-α regulates the expression of PDGF-B, an shRNA 
plasmid specific for SDF-1α (shSDF-1α) was used to down-regulate SDF-1α mRNA and 
protein levels in C3H/10T1/2 (10T1/2) mouse mesenchymal-like cells and to look for its 
effect on PDGF-B. 10T1/2 cells, which endogenously express SDF-1α and PDGF-B, were 
transfected with 1µg of either the shSDF-1α or shcontrol plasmid and maintained under 
puromycin selection (2µg/mL) for the duration of the experiments. Using PCR, qPCR 
(Figure 5A and B) and ELISA (Figure 5C), down-regulation of SDF-1α mRNA and protein 
levels in 10T1/2 cells transfected with either shSDF-1α (10T1/2-sh-SDF-1α) or shcontrol 
(10T1/2-sh-control) was quantified. We found that down-regulating SDF-1α expression in 
10T1/2 cells also down-regulated PDGF-B mRNA levels (Figure 5A and B).  
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Figure 5A. PCR to detect SDF-1α and PDGF-B mRNA  
 
 
 
 
 
Figure 5B. qPCR to confirm SDF-1α and PDGF-B mRNA down-regulation 
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Figure 5C. ELISA assay to confirm down-regulation of SDF-1α protein levels 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Down-regulating SDF-1α decreases PDGF-B mRNA levels. 10T1/2 cells were 
transfected with 1µg shSDF-1α (10T1/2-sh-SDF-1) or shcontrol (10T1/2-sh-control) using FuGENE 
6 and maintained under puromycin selection for the duration of the experiments. SDF-1α and 
PDGF-B mRNA levels were analyzed and quantified by (A) PCR and (B) qPCR. SDF-1α and 
PDGF-B mRNA levels were down-regulated in 10T1/2-shSDF-1 compared to 10T1/2-shcontrol. 
(C) Supernatant from either 10T1/2-sh-SDF-1or 10T1/2-sh-control was collected, concentrated and, 
analyzed by ELISA. Bar graph shows pooled data from three independent experiments each 
performed in triplicate. P < 0.05 was considered significant. SDF-1α protein levels are down-
regulated in 10T1/2-shSDF-1 compared to 10T1/2-shcontrol. 
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Summary 
  
We previously demonstrated that treating TC/siVEGF7-1 tumors with Ad-SDF-1α 
up-regulated PDGF-B mRNA levels (40). In this section, we investigated the role of SDF-
1α as a regulator of PDGF-B expression both in vitro and in vivo.  
We treated both the TC/siVEGF7-1 and HEK293 cells with either the recombinant 
human SDF-1α or the inactive 9SDF-1α protein and found that SDF-1α up-regulated 
PDGF-B mRNA and protein levels in vitro. To confirm that SDF-1α also up-regulated 
PDGF-B protein levels in vivo, tumor sections from the Ad-SDF-1α treated tumors were 
stained for PDGF-B. We found that SDF-1α up-regulated PDGF-B protein levels in vivo. In 
contrast, we used an shRNA plasmid specific for SDF-1α and down-regulated SDF-1α 
mRNA and protein levels in 10T1/2 cells. We found that down-regulating SDF-1α also 
down-regulated PDGF-B.  
 Many cancers, including colorectal cancer, pancreatic cancer, glioma, and sarcoma, 
overexpress PDGF-B (53). However, the mechanism by which PDGF-B is up-regulated 
remains unclear. Studies by Onimaru and colleagues demonstrated that VEGFC can 
regulate vascular stabilization by controlling PDGF-B expression (67). In the current study, 
we are the first to demonstrate the SDF-1α regulates PDGF-B. These findings illustrate the 
importance of SDF-1α in the tumor microenvironment not only as a chemotactic factor for 
BMC migration, but also, as a regulator of other angiogenic factors such as PDGF-B which 
are critical for tumor blood vessel development. 
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Chapter 3. 
SDF-1α regulates PDGF-B via a transcriptional mechanism which involves binding of 
the ELK-1 transcription factor to the pdgf-b promoter  
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Rationale 
 
Stromal derived growth factor (SDF-1α) binds to its 7-transmembrane G-protein 
coupled receptor CXCR4 expressed on the surface of cells. Once SDF-1α binds to CXCR4, 
several down-stream signaling pathways linked to transcription and expression through the 
MEK1/2 and ERK1/2 are induced. ERK can then phosphorylate and activate other cellular 
proteins as well as translocate to the nucleus and phosphorylate and /or activate 
transcription factors such as the ELK-1 transcription factor (64, 68). The ELK-1 nuclear 
transcription factor is a member of the three ternary complex factors (TCFs), a subfamily of 
the E twenty-six (Ets) domain transcription factors. TCFs are involved in several biological 
processes and have been shown to be important in regulating angiogenesis and 
vasculogenesis (59, 62, 63).  
PDGF-B expression has been shown to be over-expressed in several cancers such as 
sarcomas and gliomas (53, 54). However, the mechanism by which PDGF-B is up-
regulated during vascular remodeling remains unclear. In the previous section, we 
demonstrated that SDF-1α regulates PDGF-B expression both in vitro and in vivo. Since 
PDGF-B is regulated via several mechanisms, including transcriptional regulation (60), we 
investigated whether SDF-1α regulates PDGF-B via a transcriptional mechanism and 
whether this regulation involves binding of the ELK-1 transcription factor to the pdgf-b 
promoter.  
We cloned the 2kb pdgf-b promoter into the pGL3 luciferase reporter vector (pdgf-
b/pGL3) and showed that SDF-1α activates the pdgf-b promoter in both the TC/siVEGF7-1 
and HEK293 cell lines. We then used the GeneRegulation.com software and identified 
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potential ELK-1 binding sites. 3 sites which scored above 85% were investigated at -600 
bp, and the transcription start site (TS) within the pdgf-b promoter and, at +1 Kb within the 
transcribed region. We used chromatin immunoprecipitation and showed that ELK-1 binds 
to the pdgf-b promoter at the -600 bp site with a peak at 30 minutes after SDF-1α 
stimulation in both the TC/siVEGF7-1 and HEK293 cell lines. In contrast, ELK-1 did not 
bind to the TS site in either cell lines while it bound to the + 1Kb site only in the 
TC/siVEGF7-1 cells. We are the first to demonstrate that SDF-1α regulates PDGF-B via a 
transcriptional mechanism which involves binding of the ELK-1 transcription factor to the 
pdgf-b promoter.  
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Results 
 
SDF-1α regulates PDGF-B expression via transcription 
To demonstrate that SDF-1α regulates the expression of PDGF-B via a 
transcriptional mechanism, both the TC/siVEGF7-1 and HEK293 cell lines were transfected 
with 50ng/mL of either the pdgf-b/pGL3 construct we generated or the pGL3 control vector 
for 48 hours. The cells were then plated in the absence of growth factors and supplements 
for 24 hours and treated with 100ng/ml of either the human recombinant SDF-1α or the 
9SDF-1α inactive protein for 8 hours. The cells were lysed and the luciferase signal was 
measured and quantified to analyze pdgf-b promoter activity. SDF-1α activated the pdgf-b 
promoter compared to 9SDF-1α in both TC/siVEGF7-1 and HEK293 cells (Figure 6).  
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Figure 6. SDF-1α regulates PDGF-B expression via transcription. TC/siVEGF7-1 and HEK293 
cells were transfected with either the pdgf-b/pGL3 luciferase construct or the pGL3 control vector 
for 48 hours. The cells were plated in the absence of growth factors and supplements for 24 hours 
and then treated with 100ng/ml of either SDF-1α or 9SDF-1α inactive protein for 8 hours. The cells 
were lysed and the luciferase signal quantified. Bar graph shows pooled data from three independent 
experiments each performed in triplicate. P < 0.05 was considered significant. SDF-1α activates the 
pdgf-b promoter in both TC/siVEGF7-1 and HEK293 cells. 
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SDF-1α induces binding of the ELK-1 transcription factor to the pdgf-b promoter  
To determine whether the ELK-1 transcription factor binds to the pdgf-b promoter 
in response to SDF-1α stimulation, ELK-1 binding sites were identified both within the 
pdgf-b promoter and the transcribed region using the GeneRegulation.com MATCH 
software. Three binding sites which scored above 85% were investigated at -600 bp, the 
transcription start site (TS) and, at the +1 kb site (Figure 7A). TC/siVEGF7-1 and HEK293 
cells were plated in the absence of growth factors and supplements for 24 hours and then 
treated with 100ng/ml of the SDF-1α recombinant human protein for 15, 30 and, 60 
minutes. Chromatin immunoprecipitation (ChIP) was performed and ELK-1 binding was 
quantified using q-PCR.  
ELK-1 binds to the pdgf-b promoter with high affinity at the -600 bp site in both 
TC/siVEGF7-1 and HEK293 cells (P < 0.05; Figure 7B and C), does not bind with high 
affinity at the TS site (P > 0.05; Figure 7D) and, binds to the + 1 Kb site in the 
TC/siVEGF7-1 but not in the HEK293 cells (Figure 7E). We speculate that the large error 
bars observed at the TS site (Figure 7D) are due to the cycling of the ELK-1 transcription 
factor between a bound and unbound state. ELK-1 recognizes and binds the TS binding site 
but is quickly released suggesting that this site is not critical for the activation of the pdgf-b 
promoter in response to SDF-1α. As for binding of ELK-1 to the +1 kb site in the 
TC/siVEGF7-1 cells, further studies are required to analyze its potential role in promoting 
PDGF-B transcription in response to SDF-1α. 
Figure 7A. Schematic representing the 3 investigated ELK-1 binding sites 
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Figure 7B. qPCR quantification of ELK-1 binding at the – 600bp site  
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Figure 7C. Representative gel depicting ELK-1 binding at the – 600bp site in 
TC/siVEGF7-1 cells with a peak at 30 minutes post stimulation with SDF-1α 
 
 
 
 
 
 
Figure 7D. qPCR quantification of ELK-1 binding at the transcription start (TS) site  
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Figure 7E. qPCR quantification of ELK-1 binding at the + 1 kb site 
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Figure 7. The ELK-1 transcription factor binds to pdgf-b promoter in response to SDF-1α. (A) 
Schematic representation of the potential ELK-1 binding sites within the promoter and the 
transcribed region. Using GeneRegulation.com MATCH software, 3 potential ELK-1 binding sites 
which scored >85% were investigated at -600 bp (blue box 1), at the transcription start site (TS; 
blue box 2) and, at the + 1 Kb site (blue box 3). Primer binding sites for the corresponding regions 
are also illustrated. (B,C,D,E) TC/siVEGF7-1 and HEK293 cells were plated and cultured in the 
absence of growth factors and supplements for 24 hours, then treated with 100ng/ml of SDF-1α for 
15, 30 or 60 minutes. Chromatin immunoprecipitation (ChIP) was performed and ELK-1 binding at 
each of the 3 different sites was quantified using qPCR. The data is represented as fold increase in 
ELK-1 binding scaled from 0 (non-binding) to 1 (complete binding). Bar graph shows pooled data 
from three independent experiments each performed in triplicate. The sample values minus the 
control values were used in one-way analysis of variance. Negative numbers were replaced with 0 
indicating non-binding. P < 0.05 was considered significant. (B, C) ELK-1 binds to the pdgf-b 
promoter at the -600bp site with a peak at 30 minutes post stimulation with SDF-1α. The qPCR 
samples were run on a 1% agarose gel confirming ELK-1 binding at the – 600 bp site with a peak at 
30 minutes. (D) ELK-1 does not bind with high affinity at the TS site; however, (E) it binds at the 
+1 Kb site in TC/siVEGF7-1 cells but not in the HEK293 cells.  
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The ELK-1 transcription factor is phosphorylated at serine 383 in response to SDF-1α 
in HEK293 ChIP samples 
To further demonstrate that the ELK-1 transcription factor is activated in response 
to SDF-1α stimulation, a fraction of the lysates from the HEK293
 
cells collected for ChIP 
(as previously described) were also used in a western blot analysis to detect both 
phosphorylated ELK-1(S383) and total ELK-1. The ELK-1 transcription factor is a member 
of the ETS family of transcription factors which has been reported to be activated in 
response to the MAPK (ERK1/2) pathway by phosphorylation, specifically at serine 383 
(61, 64). We found that SDF-1α induced phosporylation of the ELK-1 transcription factor 
at S383 with a peak at 30 minutes post stimulation coinciding with the previous ChIP 
findings (Figure 8A and B). These observations suggest that the ELK-1 transcription factor 
plays a critical role in the transcription of PDGF-B in response to SDF-1α.  
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Figure 8. ELK-1 is phosphorylated at S383 in response to SDF-1α in HEK293 ChIP samples. 
HEK293 cells were plated and cultured in the absence of growth factors and supplements for 24 
hours then treated with 100ng/ml of SDF-1α for 15, 30 or 60 minutes. The nuclear protein fractions 
were isolated as described for the ChIP assay, combined with 2x SDS loading buffer and boiled at 
100 OC for 5 minutes. Western blot analysis was performed and the membrane was probed for 
phospho-ELK-1(S383).  (A) Representative blot illustrating phospho-ELK-1(S383), total ELK-1 
and, Lamin B nuclear loading control bands. (B) Bar graph from 3 independent western blots 
depicting the fold increase in phospho-ELK-1(S383) as measured from the corresponding 
densitometry. Both phospho-ELK-1(S383) and total ELK-1 were normalized to Lamin B and the 
densitometry was calculated as the ratio of normalized phospho-ELK-1(S383) to normalized total 
ELK-1. P < 0.05 was considered significant. SDF-1α induced phosphorylation of ELK-1 at S383 
with a peak at 30 minutes. 
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Summary 
 
Many cancers, including colorectal cancer, pancreatic cancer, glioma, and sarcoma, 
over-express PDGF-B (53). However, the mechanisms by which PDGF-B expression is up-
regulated during vascular remodeling remains unclear. In the previous sections, we 
demonstrated that SDF-1α regulated PFGF-B expression in vitro in both TC/siVEGF7-1 and 
HEK293 cells and in vivo in TC/siVEGF7-1 tumors. PDGF-B expression can be regulated 
by several mechanisms, including transcriptional regulation (60).  
Signaling through the SDF-1α/CXCR4 pathway initiates a cascade of several signal 
transduction pathways linked to transcription and expression through MEK1/2 and ERK1/2. 
ERK can then phosphorylate and activate other cellular proteins as well as translocate to the 
nucleus, phosphorylate and/or, activate transcription factors (33). Binding of SDF-1α to 
CXCR4 induces phosphorylation of the mitogen-activated protein kinases (MAPKs) p44 
ERK-1 and p42 ERK-2, which subsequently initiates the phosphorylation of several down-
stream transcription factors including the nuclear transcription factor ELK-1 (64). Here, we 
investigated whether SDF-1α regulated PDGF-B expression via a transcriptional 
mechanism which involves binding of the ELK-1 transcription factor.  
We cloned the 2 Kb pdgf-b promoter into the pGL3 reporter vector and showed that 
SDF-1α regulates PDGF-B expression via a transcriptional mechanism in both 
TC/siVEGF7-1 and HEK293 cells. We then used the GeneRegulation Match software and 
identified potential ELK-1 binding sites within the pdgf-b promoter and transcribed region. 
Using ChIP, we then demonstrated that the ELK-1 transcription factor binds to the pdgf-b 
promoter in response to SDF-1α at the -600 bp site in both TC/siVEGF7-1 and HEK293 
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cells with a peak at 30 minutes post stimulation. Furthermore, we performed western blot 
analysis on a portion of the nuclear proteins obtained from the ChIP assay to confirm 
phosphorylation and activation of the ELK-1 transcription factor in response to SDF-1α. 
SDF-1α induced activation and phosphorylation of ELK-1 at serine 383 with a peak at 30 
minutes which coincided with its binding to the pdgf-b promoter with a peak at 30 minutes 
post stimulation.  
 We are first to demonstrate that SDF-1α regulates PDGF-B via a transcriptional 
mechanism which involves binding of the ELK-1 transcription factor to the pdgf-b 
promoter.  
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Chapter 4. 
The SDF-1α/PDGF-B pathway induces the differentiation of bone marrow progenitor 
cells (BMCs) into pericytes in vitro 
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Rationale 
 
We previously demonstrated that treating VEGF165-inhibited TC/siVEGF7-1 tumors 
with Ad-SDF-1α partially restored vasculogenesis and induced infiltration of BMCs to a 
perivascular area. These BMCs differentiated into pericytes/vSMCs. We also showed that 
Ad-SDF-1α up-regulated PDGF-B mRNA levels in TC/siVEGF7-1 tumors (40). In the 
previous sections we confirmed that SDF-1α regulates PDGF-B RNA and protein levels 
both in vitro and in vivo via a transcriptional mechanism which involved binding of the 
ELK-1 transcription factor to the pdgf-b promoter.  
When secreted in its homodimer form, PDGF-BB binds to its tyrosine kinase 
receptor PDGFR-β. PDGF-B and PDGFR-β are expressed in the developing vasculature, 
where PDGF-B is produced by endothelial cells, and PDGFR-β is expressed by mural cells 
such as pericytes and vascular smooth muscle cells (49). The role of PDGF-B and PDGFR-
β in pericyte differentiation has been extensively described (53, 66). Pericytes are recruited 
by PDGF-B-expressing endothelial cells to remodel, stabilize and mature the new vascular 
tube. In fact, PDGFR-β+ pericyte progenitor cells (PPPs) have been reported to migrate to 
sites of tumor growth where they differentiate into NG2+, desmin+ and α-SMA+ pericytes 
(57).  
All together, these observations suggested a correlation between the up-regulation 
of PDGF-B by SDF-1α and the differentiation of BMCs into pericytes observed in the Ad-
SDF-1α treated TC/siVEGF7-1 tumors. In this section, we investigated whether the SDF-
1α/PDGF-B pathway plays a role in the differentiation of BMCs into pericytes in vitro.  
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We established an in vitro pericyte differentiation model where BMCs were flushed 
from the hind femurs of mice and cultured in either DMEM complete medium alone or, in 
conditioned medium from 10T1/2, 10T1/2-sh-SDF-1 or, 10T1/2-sh-control cells which we 
previously generated (chapter 2; Figure 3). Although no general marker exists for the 
detection of pericytes, several markers are currently used for the identification of these 
cells. Depending on the tissue and developmental or angiogenic state of a blood vessel, the 
expression pattern of pericyte markers can vary. The most commonly used markers are, the 
early pericyte marker PDGFR-β also expressed on BM-derived progenitor cells; RGS-5, 
which detects differentiating pericytes and, desmin, α-SMA and, NG2 which are expressed 
on mature pericytes (42). α-SMA is also highly expressed by vascular smooth muscle cells 
so for the purpose of our studies, we used NG2 and desmin as markers for mature 
differentiated pericytes. 
As expected, we found that fresh BMCs expressed the PDGFR-β early pericyte 
marker but did not express both NG2 and desmin mature pericye markers. However, 
PDGFR-β+ BMCs differentiated into mature pericytes, as defined by their morphology and 
the expression of desmin and NG2, when cultured in conditioned medium from 10T1/2 
cells or 10T1/2-conditoned medium compared to DMEM medium alone or 10T1/2-sh-SDF-
1 conditioned medium. These findings, combined with our precious observations that 
10T1/2-sh-SDF-1 cells express low or no SDF-1α and PDGF-B, confirmed the critical role 
of the SDF-1α/PDGF-B pathway in BM-derived pericyte differentiation in vitro.  
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Results 
 
Fresh BMCs express PDGFR-β but do not express NG2 and desmin mature pericyte 
markers 
We investigated the expression of the 3 pericyte markers PDGFR-β, desmin and, 
NG2 on freshly collected BMCs prior to culture in vitro. BMCs were flushed from the hind 
femurs of mice, immediately cytospun onto glass slides, fixed and stained for the 
expression of PDGFR-β, NG2 and desmin (red staining). As anticipated, we found that 
fresh BMCs express the early pericyte marker PDGFR-β but do not express the mature 
pericyte markers desmin and NG2 (Figure 9). Therefore and for the rest of this study, we 
identified mature pericytes as cells with pericyte-like morphology (Figure 10A) and which 
express both the desmin and NG2 mature pericyte markers.  
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Figure 9. Freshly isolated BMCs express the early pericyte marker PDGFR-β but do not 
express desmin and NG2 mature pericyte markers. Immunocytochemistry staining. BMCs were 
flushed from the hind femurs of mice, cytospun onto glass slides, fixed, and stained for (A) 
PDGFR-β, desmin, and NG2 (red). (B) Negative staining control. No primary IgG was added, only 
the goat anti-rabbit Alexa flour 594 secondary alone (red). Blue represents Hoechst nuclear staining. 
Fresh BMCs express the early PDGFR-β pericyte marker but do not express desmin and NG2 
mature pericyte markers.  
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BMCs differentiate into pericytes when cultured in conditioned medium from 10T1/2 
cells 
To confirm that BMCs differentiate into mature pericytes in response to soluble 
growth factors present in the 10T1/2 conditioned medium, whole BMCs were flushed from 
the hind femurs of mice and cultured in a 2-well chamber slide in either DMEM complete 
medium alone or, in conditioned medium obtained from 10T1/2 cells for a period of 2 
weeks. 10T1/2 cells endogenously express SDF-1α and PDGF-B. We found that BMCs 
differentiate into pericytes, as judged by morphology (Figure 10A) and for the expression 
of NG2 and desmin mature pericyte markers (red staining; Figure 10B) when cultured in 
conditioned medium from 10T1/2 cells compared to DMEM complete medium alone.  
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Figure 10. 10T1/2 conditioned medium induces BMCs to differentiate into pericytes as defined 
by morphology and the expression of NG2 and desmin. In vitro pericyte differentiation model. 
BMCs were flushed from the hind femurs of mice and cultured in either conditioned medium from 
10T1/2 cells or DMEM complete medium alone for 2 weeks. When cultured in 10T1/2 conditioned 
medium, (A) PDGFR-β+ BMCs attach to the plate and acquire pericyte-like morphology and (B) 
express the mature pericyte markers desmin and NG2 (red). Blue represents Hoechst nuclear 
staining. The negative staining control was the same as in Figure 9B. BMCs differentiate into 
mature pericytes that express NG2 and desmin when cultured in 10T1/2 conditioned medium.  
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BMCs do not differentiate into pericytes when cultured in 10T1/2-sh-SDF-1 
conditioned medium compared to 10T1/2-sh-control medium 
We showed that PDGFR-β+ BMCs can differentiate into mature pericytes as judged 
by morphology and expression of NG2 and desmin mature pericyte markers (Figure 10) 
when cultured in conditioned medium from 10T1/2 cells. To confirm that the SDF-
1α/PDGF-B pathway plays a role in this differentiation process, we investigated whether 
PDGFR-β+ BMCs can differentiate into mature pericytes when cultured in conditioned 
medium collected from 10T1/2-sh-SDF-1. 10T1/2-shSDF-1 cells do not express SDF-1α 
and PDGF-B (Figure 5). BMCs were collected from the hind femurs of mice and cultured 
in a 2-well chamber slide in conditioned medium from either 10T1/2-shSDF-1 or 10T1/2-
shcontrol for 2 weeks. We found that PDGFR-β+ BMCs behave in a manner similar to cells 
cultured in DMEM medium alone; they do not differentiate into mature pericytes (Figure 
11A). On the other hand, PDGFR-β+ BMCs differentiate into mature pericytes when 
cultured in 10T1/2-sh-control medium (Figure 11B). 
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Figure 11. BMCs cultured in 10T1/2-sh-SDF-1 conditioned medium do not differentiate into 
pericytes as defined by morphology and expression of NG2 and desmin. In vitro pericyte 
differentiation model. BMCs were flushed from the hind femurs of mice and cultured in conditioned 
medium from either 10T1/2-sh-SDF-1 cells or 10T1/2-sh-control cells for 2 weeks. PDGFR-β+ 
BMCs (A) attach to the plate, acquire pericyte-like morphology and, (B) stain positive for desmin 
and NG2 (red) when cultured in 10T1/2-sh-control compared to 10T1/2-sh-SDF-1 conditioned 
medium. Blue represents Hoechst nuclear staining. The negative staining control was the same as in 
Figure 9B. BMCs do not attach to the plate and differentiate into desmin and NG2 expressing 
pericytes when cultured in 10T1/2-sh-SDF-1 conditioned medium. 
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Summary 
 
Previous findings from our group showed that treating TC/siVEGF7-1 tumors with 
Ad-SDF-1α increased BMC migration to the tumor site where they predominantly 
differentiated into pericytes while synonymously increasing PDGF-B mRNA levels (40). In 
the previous sections, we investigated the correlation between SDF-1α and PDGF-B and 
found that SDF-1α regulated PDGF-B both in vitro and in vivo via a transcriptional 
mechanism involving the ELK-1 transcription factor. PDGF-B and its receptor, PDGFR-β, 
have been extensively described in the process of pericyte maturation and in fact, a lack of 
signaling through the PDGF-B/PDGFR-β pathway leads to pericyte loss and to endothelial 
changes followed by capillary dilation and rupture (51, 52). Therefore, we hypothesized 
that the SDF-1α/PDGF-B pathway plays a critical role in BM-derived pericyte 
differentiation.  
To test our hypothesis, we established an in vitro pericyte differentiation model. 
BMCs were collected from the hind femurs of mice and cultured in DMEM medium alone 
or in medium from 10T1/2 cells. We found that BMCs differentiate into PDGFR-β, desmin 
and, NG2 positive pericytes when cultured in 10T1/2 medium. A study by Gabriele Bergers 
and colleagues reported the discovery of PDGFR-β-expressing pericyte progenitor cells 
(PPPs) which possess the capacity to differentiate into NG2+, desmin+ and, alpha-smooth 
muscle actin+ pericytes within tumors (57).  
In order to confirm that BMCs differentiated into pericytes when cultured in 10T1/2 
conditioned medium due to soluble growth factors present within the 10T1/2 conditioned 
medium, we collected fresh BMCs and immediately tested them for the expression of 
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PDGFR-β, desmin and, NG2. As expected, we found that fresh BMCs expressed the early 
pericyte marker PDGFR-β but did not express the desmin and NG2 mature pericyte 
markers.  
Furthermore and to characterize the role of the SDF-1α/PDGF-B pathway in the 
process of BM-derived pericyte differentiation in vitro, we collected PDGFR-β+ BMCs 
from hind femurs of mice and cultured them in either 10T1/2-sh-SDF-1 or 10T1/2-sh-
control medium. As described in chapter 2, 10T1/2-sh-SDF-1 cells do not express SDF-1α 
and PDGF-B compared to 10T1/2-sh-control cells (Figure 5). We found that PDGFR-β+ 
BMCs did not differentiate into mature pericytes when cultured in 10T1/2-sh-SDF-1 
medium.  
Our data confirmed that the SDF-1α/PDGF-B pathway plays a critical role in BM-
derived pericyte differentiation in vitro. In the next sections, we investigated the role of this 
pathway in BM-derived pericyte differentiation in vivo in Ewing’s sarcoma tumors.  
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Chapter 5. 
 
The SDF-1α antagonist AMD 3100 negatively impacts tumor vessel development in 
the Ewing’s sarcoma tumor model 
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Rationale 
 
Our group previously demonstrated that the soluble vascular endothelial growth 
factor VEGF165 is the chemotactic stimulus for BMC migration during vasculogenesis of 
Ewing’s sarcoma (10, 16, 23). We used an siRNA specific for VEGF165 and generated the 
TC/siVEGF7-1 cell line and showed that inhibiting VEGF165 decreased vasculogenesis, 
inhibited TC/siVEGF7-1 tumor growth and, decreased SDF-1α expression (40). SDF-1α is a 
chemotactic factor for BMCs and plays a critical role in the mobilization of BMCs from the 
BM to the peripheral blood (28, 31); therefore, we re-introduced SDF-1α into the 
TC/siVEGF7-1 tumors and showed that SDF-1α rescued tumor growth by restoring the 
infiltration of BMCs to a perivasular area and inducing their differentiation into pericytes 
(40).  
These observations suggested a critical role for the SDF-1α chemokine in Ewing’s 
sarcoma tumor growth. Specifically, we hypothesized that SDF-1α plays a critical role in 
Ewing’s sarcoma neo-vascularization. In order to investigate this hypothesis, we needed to 
specifically inhibit SDF-1α signaling in vivo and document its effect on the tumor blood 
vessels.  
The SDF-1α antagonist AMD 3100 
AMD3100 is a bicyclam derivative (1,1’-[1,4-phenylenebis(methylene)]-bis-
1,4,8,11-tetraazacyclotetradecane) which selectively and reversibly blocks SDF-1α from 
binding to its CXCR4 receptor. AMD3100 is currently used in the clinic in patients 
undergoing allogeneic transplantation due its low toxicity and its specificity in disrupting 
the SDF-1α/CXCR4 axis (69, 70).  
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AMD 3100 and Ewing’s sarcoma  
In this section, we investigated the role of SDF-1α on Ewing’s sarcoma tumor blood 
vessel development by specifically inhibiting SDF-1α signaling using the SDF-1α 
antagonist, AMD 3100. Nude mice were subcutaneously injected with either TC71 or 
A4573 Ewing’s sarcoma cells and once the tumors became palpable, the mice received 
daily subcutaneous injections of either PBS or 5mg/kg of the AMD3100 drug for the 
duration of the experiment. The experiment was terminated, the mice were all sacrificed 
and, the tumors resected for further analysis once the longest tumor measurment in the PBS 
control group reached the size of 2 centimeters. This constitutes the maximum size allowed 
by the Institutional Animal Care and Use Committee at The University of Texas M.D. 
Anderson Cancer Center. The tumors were resected and the vessel morphology and density 
analyzed by staining for the CD31 endothelial cell marker. In order to analyze whether 
AMD 3100 decreased blood flow to the tumors compared to PBS, we repeated the 
experiment; however, prior to resecting the tumors, we injected the mice with the Hoechst 
nuclear dye to label perfused blood vessels. We also stained the tumor sections for 
apoptosis using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) to 
confirm vascular deficiency in response to AMD 3100. 
We found that inhibiting SDF-1α signaling in both TC71 and A4573 Ewing’s 
sarcoma tumors resulted in smaller vessels with smaller lumens, decreased the microvessel 
density, decreased blood vessel perfusion and, increased tumor cell apoptosis.  
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Results 
 
AMD 3100 leads to smaller vessels with smaller lumens in both TC71 and A4573 
Ewing’s sarcoma tumors 
To investigate the role of SDF-1α on blood vessel morphology in Ewing’s sarcoma 
tumors, nude mice were subcutaneously injected with either TC71 or A4573 Ewing’s 
sarcoma cells. Once the tumors became palpable, the mice received a daily subcutaneous 
injection of either PBS alone or 5mg/kg AMD 3100 for the duration of the experiment. All 
animals were sacrificed once the longest tumor measurement in the PBS control group 
reached 2 centimeters. The tumors were resected, snap frozen in OCT and, stored for 
further analysis by IHC. Tumor sections were stained for the CD31 endothelial cell marker 
(red staining) in order to label all the tumor vessels. We found that inhibiting SDF-1α 
signaling, led to smaller more punctuated vessels with smaller lumens compared to the PBS 
group (Figure 12).  
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Figure 12. Tumor vessels are smaller with smaller lumens in response to AMD 3100 in both 
TC71 and A4573 Ewing’s sarcoma tumors. Immunohistochemistry (IHC). Nude mice were 
implanted subcutaneously with either TC71 (top row) or A4573 (bottom row) Ewing’s sarcoma 
cells. Once the tumors became palpable, the mice received daily subcutaneous injections of either 
PBS or 5 mg/kg AMD 3100. The tumors were resected once the longest tumor side measurement in 
the PBS control group reached a size of 2 centimeters (3 weeks post cell injection) and stained for 
the CD31 endothelial cell marker to label the tumor vasculature (red). Pictures were captured with a 
Zeiss Axioplan fluorescence microscope. 10x magnification.  AMD 3100 treatment leads to tumors 
with smaller vessels and smaller lumens compared to PBS.  
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AMD 3100 decreases the overall microvessel density in both TC71 and A4573 Ewing’s 
sarcoma tumors 
We demonstrated that inhibiting SDF-1α in both TC71 and A4573 tumors changed 
the vessel morphology and led to smaller vessels with smaller lumens (Figure 12). To 
investigate whether AMD 3100 decreased the tumor microvessel density in both TC71 and 
A4573 tumors as well, tumor sections were stained for the CD31 endothelial cell marker 
(red staining) as previously described to label the tumor vasculature and, the total amount 
of positive pixels for CD31 from both the PBS and AMD 3100 treated mice was quantified 
using the SimplePCI software. Note that any CD31+ cell, whether a single cell or a vessel-
like structure, was included in the quantification. Treating the mice with AMD 3100 
decreased the tumor microvessel density compared to PBS in both TC71 and A4573 
Ewing’s tumors (Figure 13).  
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Figure 13. The total microvessel density is decreased in response to AMD 3100 in both TC71 
and A4573 Ewing’s sarcoma tumors. Microvessel density. Nude mice were implanted 
subcutaneously with either TC71 or A4573 Ewing’s sarcoma cells. Once the tumors became 
palpable, the mice received daily subcutaneous injections of either PBS or 5 mg/kg AMD 3100. All 
tumors were resected 3 weeks post cell injection and stained for the CD31 endothelial cell marker. 
10 x magnification. The total positive pixels for CD31 were quantified using the SimplePCI 
software. P < 0.05 was considered significant. The total microvessel density was reduced by 49 % 
in TC71 tumors and by 55.5 % in A4573 tumors.  
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AMD 3100 decreases the amount of perfused blood vessels in both TC71 and A4573 
Ewing’s sarcoma tumors  
So far, our results demonstrated that using AMD 3100 to inhibit SDF-1α from 
binding CXCR4 negatively impacted the tumor vasculature; it led to smaller vessels with 
smaller lumens and decreased the microvessel density. To investigate whether the blood 
vessels in the AMD 3100-treated mice were less efficient in delivering blood to the tumor 
site, the experiment was repeated as previously described; however and, prior to sacrificing 
the mice, we performed an intravenous (i.v.) injection using the Hoechst33342 dye in order 
to label any perfused blood vessels in both the PBS and AMD 3100 treated mice. 
Hoechst33342 is a nuclear dye which will label any cell it comes in contact with blue. 
Tumor sections were fixed and the total amount of positive pixels for Hoechst33342 (blue 
staining) was quantified using the SimplePCI software. Inhibiting SDF-1α signaling not 
only changed the vessel morphology and decreased the total microvessel density but, it also 
decreased the total amount of perfused blood vessels compared to the mice treated with 
PBS (Figure 14).  
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Figure 14. AMD 3100 decreased the total amount of perfused blood vessels in both 
TC71 and A4573 Ewing’s tumors. Immunohistochemistry (IHC). Nude mice were 
implanted subcutaneously with either TC71 (top row) or A4573 (bottom row) Ewing’s sarcoma 
cells. Once the tumors became palpable, the mice received daily subcutaneous injections of either 
PBS or 5 mg/kg AMD 3100. Immediately prior to resecting the tumors, the mice received an i.v. 
injection of the Hoechst33342 dye to label perfused vessels (blue). 10x magnification. The total 
positive pixels for Hoechst33342 were quantified using the SimplePCI software. P < 0.05 was 
considered significant. Vessel perfusion was reduced by 71.2 % in TC71 tumors and by 47.5 % in 
A4573 tumors.  
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AMD 3100 increases tumor cell apoptosis in both TC71 and A4573 Ewing’s sarcoma 
tumors  
To investigate the effect of the observed changes in vessel morphology, density and, 
perfusion on tumor cell viability in both TC71 and A4573 Ewing’s sarcoma tumors in 
response to AMD 3100 and inhibiting SDF-1α signaling, we performed TUNEL staining 
(brown) on the tumor sections to look for tumor cell apoptosis. The total amount of positive 
brown pixels was quantified using the SimplePCI software. AMD 3100 increased tumor 
cell apoptosis in both TC71 and A4573 Ewing’s sarcoma tumors compared to PBS (Figure 
15).  
Figure 15A. TUNEL staining to detect tumor cell apoptosis  
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Figure 15B. Quantification for TUNEL staining  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. AMD 3100 increases tumor cell apoptosis in both TC71 and A4573 Ewing’s 
sarcoma tumors. (A) TUNEL staining (brown). Nude mice were implanted subcutaneously with 
either TC71 (top row) or A4573 (bottom row) Ewing’s sarcoma cells. Once the tumors became 
palpable, the mice received daily subcutaneous injections of either PBS or 5 mg/kg AMD 3100 for 3 
weeks. Tumors were resected and tumor sections stained for tumor cell apoptosis using TUNEL. 
10x magnification. B) The total positive pixels for TUNEL were quantified using the SimplePCI 
software. P < 0.05 was considered significant. Apoptosis was increased by 2.4 folds in TC71 tumors 
and by 2.77 folds in A4573 tumors in response to AMD3100.   
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Summary 
 
The SDF-1α/CXCR4 axis has been implicated in several biological processes; it is 
involved in homeostasis and functions to regulate hematopoietic cell trafficking and 
secondary lymphoid tissue architecture (31, 33). In adult life, SDF-1α plays an important 
role in the retention and homing of BM progenitor cells to the BM (28, 34). Overall, the 
role of SDF-1α as a chemotactic gradient for CXCR4 (+) BM progenitor cells and its 
implication in embryonic and adult postischemia and in tumor angiogenesis has been 
extensively described (35-37).  Our group demonstrated that introducing SDF-1α into 
VEGF165-inhibited TC/siVEGF7-1 tumors partially restored vasculogenesis with infiltration 
of BMCs to a perivasular area and rescued tumor growth (40). These observations 
suggested a critical role for the SDF-1α chemokine in blood vessel development during 
Ewing’s sarcoma tumor growth.  
In this section, in order to investigate the role of SDF-1α in Ewing’s sarcoma, we 
used the AMD 3100 drug which specifically disrupts the SDF-1α/CXCR4 axis (69, 70) and 
analyzed its effect on tumor blood vessels in both TC71 and A4573 Ewing’s sarcoma 
tumors. Nude mice were subcutaneously injected with either TC71 or A4573 Ewing’s cells 
and once the tumors became palpable, the mice received daily subcutaneous injections of 
either PBS or 5 mg/kg AMD 3100 for the duration of the experiment.  
The tumors were resected and tumor sections were stained for the CD31 endothel1al 
cell marker to label the blood vessels. We found that inhibiting SDF-1α signaling 
negatively impacted the tumor vessels; the vessel morphology indicated smaller and more 
punctuated vessels with smaller lumens. Furthermore, we quantified the total amount of 
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CD31+ cells and found that the overall microvessel density was decreased. We i.v. injected 
the mice with the Hoechst33342 dye and found that the vessels were also less perfused in 
response to AMD 3100. All these changes led to an increase in tumor apoptosis. Although 
our findings cannot determine vessel functionality, it is safe to conclude that the vessels in 
the AMD 3100 group are less efficient in delivering blood to the tumor mass compared to 
the vessels in the PBS control group. These findings confirm our hypothesis that SDF-1α 
plays a critical role in the process of blood vessel development during Ewing’s sarcoma 
tumor growth.  
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Chapter 6. 
The SDF-1α/PDGF-B pathway plays a critical role in BM- derived pericyte 
differentiation during Ewing’s sarcoma tumor growth 
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Rationale 
 
 We demonstrated that SDF-1α signaling plays a critical role during blood vessel 
development of Ewing’s sarcoma tumors; inhibiting SDF-1α signaling in both TC71 and 
A4573 tumors negatively impacted the tumor blood vessel morphology, decreased the 
microvessel density and perfusion and, increased tumor cell apoptosis (chapter 5). Given 
that SDF-1α functions as a chemotactic stimulus for BMC migration (28, 31) and combined 
with the previous findings from our group showing that introducing SDF-1α into VEGF165 -
inhibited tumors (TC/siVEGF7-1) partially restored vasculogenesis with infiltration of 
BMCs to a perivasular area where they differentiated into pericytes (40), these observations 
suggested a role for SDF-1α signaling in vasculogenesis of Ewing’s sarcoma and 
specifically, in BM-derived pericyte differentiation which supports tumor neo-
vascularization.  
Furthermore, our studies also demonstrated that introducing SDF-1α into 
TC/siVEGF7-1 tumors increased PDGF-B mRNA levels (40). We investigated the 
correlation between SDF-1α and PDGF-B and showed that SDF-1α regulates PDGF-B 
expression both in vitro and in vivo (chapters 2 and 3). Given the role of PDGF-B and its 
receptor, PDGFR-β, in the process of pericyte maturation (51, 55) and studies showing that 
inhibiting PDGFR-β in a mouse model of pancreatic cancer depleted tumor pericytes and 
induced their detachment from the vascular endothelium which resulted in blood vessel 
hyperdilation and disruption (48), we investigated the role of the SDF-1α/PDGF-B pathway 
in BM-derived pericyte differentiation. In chapter 4, we confirmed the critical role of the 
SDF-1α/PDGF-B pathway in vitro. In this chapter, we investigated the role of this pathway 
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in vivo. We hypothesized that the differentiation of BMCs into pericytes observed in the 
Ad-SDF-1α treated TC/siVEGF7-1 tumors (40) and the negative impact observed from 
inhibiting SDF-1α signaling using AMD3100 on both the TC71 and A4573 Ewing’s 
sarcoma tumor vasculature, is in fact due to the role of SDF-1α both as a chemotactic factor 
for CXCR4+ BMC progenitors and as a regulator of PDGF-B expression.  
The effect of AMD3100 on BMC migration to both TC71 and A4573 Ewing’s 
sarcoma tumors was analyzed by performing a BMT from GFP+ transgenic mice into nude 
mice (Figure 1) and staining for BMCs at the distant tumor site. Tumor sections were 
stained for both GFP and for the CD31 endothelial cell marker to label the tumor 
vasculature and characterize the distribution of BMCs relative to it. GFP+ BMCs migrated 
to both TC71 and A4573 tumors in both PBS and AMD3100 – treated tumors; however, the 
distribution and differentiation pattern of these cells was different in both groups. GFP+ 
BMCs predominantly differentiated into endothelial cells and did not form thick 
perivascular layers surrounding the CD31+ vessels in the AMD3100 – treated mice.  
In order to confirm that BMCs do not differentiate into pericytes in the AMD3100 – 
treated group and to elucidate the role of the SDF-1α/PDGF-B pathway on BM-derived 
pericyte differentiation during vasculogenesis of Ewing’s sarcoma, we further stained the 
tumor sections for GFP in combination with both desmin and NG2, mature pericyte 
markers. We found that AMD3100 decreased BMC differentiation into pericytes in both 
TC71 and A4573 Ewing’s sarcoma tumors. We further validated our hypothesis that SDF-
1α induces BMC differentiation into pericytes via its regulation of PDGF-B by staining the 
tumor sections for the expression of PDGF-B.  We found that Inhibiting SDF-1α signaling 
in vivo down regulated PDGF-B expression.  
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All together, our data validates the critical role of the SDF-1α/PDGF-B pathway in 
BM-derived pericyte differentiation during vasculogenesis of Ewing’s sarcoma.  
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Results 
 
BMCs migrate to AMD 3100-treated tumors where they predominantly differentiate 
into ECs but do not form thick perivascular layers  
 To investigate the effect of AMD 3100 on the migration of GFP+ BMCs to both 
TC71 and A4573 Ewing’s sarcoma tumors, we performed a BMT from GFP+ transgenic 
mice into nude mice as previously described (Figure 1). Following engraftment, the mice 
were subcutaneously implanted with either TC71 or A4573 Ewing’s sarcoma cells. Once 
the tumors became palpable, the mice received a daily subcutaneous injection of either PBS 
or 5 mg/kg AMD 3100 for the duration of the experiment.  Once the longest tumor 
measurement in the PBS control group reached 2 centimeters (3 weeks following tumor cell 
injection), all the mice were sacrificed and the tumors resected. Tumor sections were 
stained for GFP+ BM-derived cells (red staining) and for CD31 endothelial cell marker 
(green staining) in order to analyze the distribution of BMCs relative to the tumor vessels. 
We found that BMCs migrated to both the AMD 3100 and PBS treated tumors; however, 
the distribution of these cells within the tumor site was changed.  BMCs preferentially co-
localized with the CD31 marker within the AMD 3100 treated tumors, indicating that these 
BMCs differentiated into endothelial cells (yellow staining) but rarely formed perivascular 
layers surrounding the vessels like the ones observed in the PBS control group (Figure 16).  
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Figure 16. BMCs migrate to both TC71 and A4573 AMD 3100-treated tumors where they 
differentiate into ECs but do not form thick perivascular layers.  Immunohistochemistry (IHC). 
TC71 (top row) or A4573 (bottom row) Ewing’s sarcoma tumors were subcutaneously implanted in 
GFP+ BM-transplanted nude mice. Tumor-bearing mice received daily subcutaneous injections of 
either PBS or 5mg/kg AMD 3100 for the duration of the experiment. (A) Tumor sections were 
stained for GFP (red) in combination with CD31, an endothelial cell marker (green). GFP+ BMCs 
that migrated to the tumor and co-localized with CD31 (yellow) are depicted by the yellow arrows. 
GFP+ BMCs that formed perivascular layers are depicted by the white arrows. (B) Negative staining 
control. No primary IgG was added only the secondary. 20 x magnification. BMCs migrate to both 
PBS and AMD 3100-treated mice. BMCs predominantly differentiate into ECs and do not form 
thick perivascular layers in the AMD 3100 group compared to the PBS control group.  
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AMD 3100 decreases the differentiation of BMCs into NG2 and desmin positive 
pericytes in both TC71 and A4573 tumors   
 Our previous findings demonstrated that BMCs migrate to both AMD 3100 and 
PBS-treated tumors; however, they do not form thick perivascular layers surrounding the 
vasculature in the AMD 3100-treated mice. To demonstrate that the decrease in the 
perivascular layer corresponded to a decrease in BM-derived pericytes, we performed a 
BMT from GFP+ mice into nude mice, subcutaneously implanted the transplanted mice 
with either TC71 or A4573 Ewing’s cells and, administered the AMD 3100 treatment as 
previously described. The tumors were harvested and tumor sections stained for GFP+ 
BMCs (red staining) in combination with desmin or NG2, pericyte markers (green 
staining). We found that inhibiting SDF-1α signaling decreased desmin+ (Figure 17A) and 
NG2+ (Figure 17B) BM-derived pericytes in both TC71 and A4573 Ewing’s tumors. 
Figure 17A. Desmin+ BM-derived pericytes  
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Figure 17B. NG2+ BM-derived pericytes 
Figure 17. AMD 3100 decreases the differentiation of BMCs into desmin and NG2 positive 
pericytes in both TC71 and A4573 Ewing’s tumors. Immunohistocemistry (IHC). TC71 (top 
row) or A4573 (bottom row) Ewing’s sarcoma tumors were implanted subcutaneously in GFP+ BM-
transplanted nude mice. The tumor-bearing mice received daily subcutaneous injections of either 
PBS or 5mg/kg AMD 3100 for the duration of the experiment. Tumors were harvested and tumor 
sections were stained for (A) GFP+ BMCs (red) in combination with desmin (green) and (B) GFP+ 
BMCs (red) in combination with NG2 (green) to identify pericytes. 20 x magnification. GFP+ 
BMCs that differentiated into pericytes (yellow) are depicted with the yellow arrows. The total 
amount of green and red pixels were quantified using the SimplePCI software and the ratio 
calculated to measure the percent decrease in BM-derived desmin and NG2 positive pericytes in 
response to AMD 3100 compared to PBS as indicated in both panels (A) and (B).  P < 0.05 was 
considered significant. AMD 3100 decreases the differentiation of BMCs into NG2+ pericytes in 
TC71 and A4573 tumors. 
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AMD 3100 decreases the total NG2 and desmin+ pericyte content in TC71 and A4573 
Ewing’s tumors 
 To investigate the effect of AMD 3100 on the overall tumor pericyte content, tumor 
sections from either the AMD 3100 or PBS treated mice were stained for the CD31 
endothelial cell marker (red staining) in combination with either desmin or NG2 mature 
pericyte markers (green staining) to analyze the amount and distribution of pericytes 
relative to the vasculature. We then quantified the total amount of green pixels in five 
random 10x fields using the SimplePCI software. We found that the desmin (Figure 18A) 
and NG2 (Figure 18B) positive pericyte content was decreased in the AMD 3100 treated 
mice and that these cells did not form thick loose layers around the vessels as observed in 
the PBS group in both TC71 and A4573 Ewing’s tumors.  
Figure 18A. Overall desmin+ tumor-associated pericytes  
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Figure 18B. Overall NG2+ tumor-associated pericytes 
Figure 18. AMD 3100 decreases the total amount of desmin and NG2 pericytes in both TC71 
and A4573 Ewing’s tumors. Immunohistochemistry (IHC).  Nude mice were subcutaneously 
implanted with either TC71 (top rows) or A4573 (bottom rows) Ewing’s sarcoma cells. Once the 
tumors became palpable, the mice received daily subcutaneous injections of either PBS or 5 mg/kg 
AMD 3100. All tumors were resected once the longest tumor side measurement in the PBS control 
group reached a size of 2 centimeters (3 weeks post cell injection). Tumor sections were stained for 
(A) CD31 endothelial cell marker (red) in combination with desmin or (B) CD31 endothelial cell 
marker (red) in combination with NG2 (green) to identify pericytes. 10 x magnification. The total 
positive amount of green pixels for each pericyte marker was quantified and the reduction in overall 
pericyte content in AMD 3100 compared to PBS-treated tumors was determined using the 
SimplePCI software. Percent reductions are indicated within both panels (A) and (B). P < 0.05 was 
considered significant. AMD 3100 decreases the overall NG2+ pericyte content in the TC71 and 
A4573 tumors.  
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AMD3100 decreases PDGF-B expression in Ewing’s sarcoma tumors 
 To demonstrate that inhibiting SDF-1α signaling in both TC71 and A4573 tumors 
also down-regulated PDGF-B expression and that the SDF-1α/PDGF-B pathway is playing 
a critical role in the differentiation of BMCs into pericytes in vivo, tumor sections from 
either PBS or AMD 3100 treated mice were fixed and analyzed for PDGF-B expression 
(brown staining). We found that AMD3100 decreased PDGF-B in both TC71 and A4573 
tumors compared to PBS (Figure 19).   
  
 
 
 
 
 
 
 
 
Figure 19. AMD 3100 decreases PDGF-B expression in both TC71 and A4573 Ewing’s tumors. 
IImmunohistochemistry (IHC). Nude mice were subcutaneously implanted with either TC71 (top 
row) or A4573 (bottom row) Ewing’s sarcoma cells. Once the tumors became palpable, the mice 
received daily subcutaneous injections of either PBS or 5 mg/kg AMD 3100. All tumors were 
resected once the longest side tumor measurement in the PBS control group reached a size of 2 
centimeters (3 weeks post cell injection). Tumor sections were fixed and stained for PDGF-B 
(brown). 10 x magnification. AMD 3100 decreases PDGF-B expression in TC71 and A4573 
tumors. 
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Summary 
 
In this section, we investigated the role of the SDF-1α/PDGF-B pathway in BM-
derived pericyte differentiation during vasculogenesis of Ewing’s sarcoma. SDF-1α 
functions as a chemotactic stimulus for CXCR4+ BMCs and has been shown to play a role 
in tumor neo-angiogenesis (31, 35, 39).  Previous findings from our lab demonstrated that 
introducing SDF-1α into VEGF165-inhibted TC71 tumors (TC/siVEGF7-1) induced 
infiltration of BMCs to a perivascular area and their differentiation into pericytes. SDF-1α 
treated TC/siVEGF7-1 tumors also displayed an increase in PDGF-B mRNA levels (40).  
In the previous sections, we investigated the correlation between SDF-1α and 
PDGF-B and demonstrated that SDF-1α regulates the expression of PDGF-B both in vitro 
and in vivo (chapters 2 and 3). Given the role of PDGF-B and its receptor PDGFR-β in the 
process of pericyte maturation (51), we then investigated the role of the SDF-1α/PDGF-B 
pathway in BM-derived pericyte differentiation and demonstrated that this pathway plays a 
critical role in the differentiation of BMCs into pericytes in vitro (chapter 4).  
Here, we treated both TC71 and A4573 tumor-bearing mice with AMD 3100 and 
showed that inhibiting SDF-1α signaling decreased the infiltration of BMCs to a 
perivascular area and their differentiation into pericytes. Furthermore, we tested the AMD 
3100-treated tumors for PDGF-B and found that PDGF-B protein expression was also 
decreased. All together, these findings validated the critical role of the SDF-1α/PDGF-B 
pathway in BM-derived pericyte differentiation in vivo in the Ewing’s sarcoma tumors.  
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Chapter 7. 
AMD 3100 does not display a therapeutic effect in the treatment of primary Ewing’s 
sarcoma tumors 
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Rationale 
 
 Ewing’s sarcoma tumors rely on an extensive vascular network for survival and 
growth (2, 6). We previously demonstrated that BMCs migrate to both TC71 and A4573 
Ewing’s sarcoma tumors, differentiate into endothelial cells and pericytes and, participate 
in tumor neo-vascularization. Further studies then confirmed that vasculogenesis is in fact 
essential for Ewing’s sarcoma growth and that VEGF165 is the chemotactic stimulus for 
BMC migration to the tumor site; inhibiting VEGF165 inhibited vasculogenesis and tumor 
growth (10, 16, 25, 65). We introduced SDF-1α into the VEGF165-inhibited tumors 
(TC/siVEGF7-1) and demonstrated that, while having no effect on VEGF165 expression, 
SDF-1α partially restored vasculogenesis and rescued tumor growth (40). All together, 
these findings emphasized the importance of vasculogenesis for Ewing’s sarcoma growth 
and suggested a role for SDF-1α in this process of tumor neo-vascularization.  
In the current study, we investigated the role of SDF-1α in vasculogenesis of 
Ewing’s sarcoma; specifically, the role of the SDF-1α/PDGF-B pathway in BM-derived 
pericyte differentiation. We found that inhibiting SDF-1α signaling in TC71 and A4573 
Ewing’s sarcoma tumors down-regulated the expression of PDGF-B while simultaneously 
inhibiting the differentiation of BMCs into pericytes (chapters 5 and 6). These findings 
confirmed the critical role of the SDF-1α/PDGF-B in the process of pericyte differentiation 
during vasculogenesis of Ewing’s sarcoma.  
 Although pericytes are present in a smaller number within tumors, studies have 
shown that targeting pericytes in addition to endothelial cells, resulted in a more efficient 
reduction in tumor vasculature than targeting one or the other alone (48). We analyzed the 
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tumor vessels in the AMD 3100 treated TC71 and A4573 Ewing’s sarcoma tumor-bearing 
mice and found that inhibiting SDF-1α signaling resulted in smaller vessels with smaller 
lumens, decreased vessel perfusion and, increased tumor apoptosis. These observations 
prompted us to investigate the effect of AMD 3100 on the overall growth of the primary 
Ewing’s sarcoma tumors and its potential as a therapeutic approach in the treatment of the 
disease.  
We subcutaneously injected TC71 or A4573 Ewing’s sarcoma cells into nude mice 
and once the tumors became palpable, the mice received subcutaneous daily injections of 
eith PBS or AMD 3100. Tumor volume was measured starting on day 1 of treatment and 
twice a week thereafter for the duration of the experiment. Once the longest tumor 
measurement in the PBS control group reached 2 centimeters (3 weeks), the mice were 
sacrificed and the final tumor volumes recorded. We found that AMD 3100 did not 
statistically reduce the TC71 or A4573 tumor volume compared to PBS. We then 
performed a survival study to investigate whether AMD 3100 stabilized the disease and 
therefore prolonged the mice survival compared to PBS. For this purpose, the mice were 
each sacrificed individually once their longest tumor measurement reached 2 centimeters. 
AMD 3100 did not increase the survival of TC71 or A4573 tumor-bearing mice compared 
to PBS.  
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Results 
 
AMD 3100 treatment leads to a trend towards decreased overall tumor volume in both 
TC71 and A4573 Ewing’s tumors  
To investigate the effect of inhibiting SDF-1α signaling and BM-derived pericyte 
differentiation on the growth of the primary Ewing’s sarcoma tumors, we subcutaneously 
injected mice with either TC71 or A4573 Ewing’s sarcoma cells and once the tumors 
became palpable, the mice received daily subcutaneous injections of either PBS alone or 
5mg/kg AMD 3100. The individual tumor volumes were recorded on day 1 of treatment 
and twice weekly thereafter for the duration of the experiment. All the mice were sacrificed 
and the tumors resected once the longest tumor measurement in the PBS control group 
reached 2 centimeters (3 weeks post injection). The volume of each individual tumor in 
either the PBS or the AMD 3100 group was recorded according to the following formula 
½.a2.b; a and b represent 2 dimensions of the tumor with a being the longest one. We found 
that although the tumors in the AMD 3100-treated mice displayed a delay in tumor growth 
and a trend towards a decreased tumor volume compared to the PBS-treated group, 
inhibiting SDF-1α signaling and specifically, the differentiation of BMCs into pericytes, did 
not statistically inhibit the growth of the primary Ewing’s tumors (Figure 20).  
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Figure 20. AMD 3100 does not statistically decrease the final TC71 and A4573 tumor volumes 
compared to PBS. Individual tumor volumes. Nude mice were subcutaneously implanted with 
either TC71 (top panel) or A4573 (bottom panel) Ewing’s sarcoma cells. Tumor-bearing mice 
received daily subcutaneous injections of either PBS or 5 mg/kg AMD 3100 for the duration of the 
experiment. All mice were sacrificed 3 weeks post tumor cell inoculation. Individual tumor volumes 
were recorded on day 1 of treatment and twice weekly thereafter. The graphs indicate the final 
individual tumor volumes from both groups recorded on day of tumor resection. The data was 
analyzed using the Mann-Whitney 2-tailed U-test software. P < 0.05 was considered significant. 
AMD 3100 results in a trend towards decreased overall tumor volumes compared to PBS.    
P > 0.05  
P > 0.05  
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AMD 3100 did not increase the survival of TC71 or A4573-tumor bearing mice  
Although inhibiting SDF-1α signaling did not statistically decrease the overall final 
tumor volume in either the TC71 or A4573 tumors compared to the PBS control group, it 
led to a trend towards a decreased tumor growth rate. We speculated that maybe AMD 3100 
prolonged the survival of the tumor-bearing mice compared to PBS by establishing a stable 
disease. In order to test this hypothesis, we repeated experiment as previously described; 
however, this time, we sacrificed the mice individually once each of the tumors’ longest 
side measurement reached 2 centimeters. AMD 3100 did not increase the survival of the 
primary tumor –bearing mice compared to PBS (Figure 21).  
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Figure 21. AMD 3100 did not increase the survival of TC71 and A4573 tumor-bearing mice. 
Survival curves. Nude mice were subcutaneously implanted with either TC71 (top panel) or A4573 
(bottom panel) Ewing’s sarcoma cells. Once the tumors became palpable, the mice received daily 
subcutaneous injections of either PBS or 5 mg/kg AMD 3100. Individual mice were sacrificed each 
at a time once their corresponding longest tumor side measurement reached a size of 2 centimeters. 
The data was analyzed using the GraphPad Prism software. P < 0.05 was considered significant. 
AMD 3100 did not increase the survival of the TC71 and A4573 primary tumor-bearing mice.  
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Summary 
 
We previously demonstrated that inhibiting SDF-1α signaling down-regulated 
PDGF-B, decreased BM-derived pericyte differentiation and, decreased vascular density. In 
this section we investigated whether the observed changes in tumor vasculature impacted 
overall tumor growth. Nude mice were subcutaneously injected with either TC71 or A4573 
Ewing’s cells. Once the tumors became palpable, the tumor volume was measured and the 
mice received daily subcutaneous injections of either PBS or AMD 3100. The tumor 
volumes were recorded twice weekly for the duration of the experiment. Once the longest 
tumor measurement of a given tumor in the PBS control group reached the maximum size 
of 2 centimeters, the entire experiment was terminated. We found that AMD 3100 treatment 
led to a trend towards decreased tumor volume; however, AMD 3100 did not statistically 
decrease tumor growth rate.  
These observations prompted us to investigate whether AMD 3100 treatment and 
loss of BM-derived pericytes stabilized tumor growth instead and prolonged the overall 
survival of he tumor-bearing mice.  To test this hypothesis, we repeated the experiment as 
previously described but this time, we sacrificed the mice individually once the longest 
tumor measurement recorded reached a maximum of 2 centimeters. We found that AMD 
3100 did not increase overall survival of the tumor-bearing mice.  
Pericytes are present in a low number in tumors and until recently, these cells have 
been considered abnormal and dysfunctional in tumors and therefore, they have been 
neglected as potential targets for anti-vascular therapy (42). Pericytes remain a functional 
constituent of the tumor vasculature and a study in 2007 showed that inhibiting PDGF-B 
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with the aptamer AX102 led to loss of pericytes and reduced vasculature in a Lewis lung 
carcinoma model and pancreatic islet cancers. However, the loss in pericytes did not retard 
tumor growth (58). In contrast, a study in pancreatic islet cancers showed that targeting 
both endothelial cells as well as pericytes resulted in more efficient reduction of tumor 
vasculature and tumor growth than targeting one or the other alone (48).  
All together, this data suggests a potential therapeutic effect for AMD 3100 as an 
anti-vascular agent if administered in combination with an anti-VEGF agent rather than a 
single anti-vascular agent alone in the treatment of Ewing’s sarcoma.  
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The pdgf-b/pGL3 vector is functional  
 To test whether the pdgf-b/pGL3 luciferase construct we generated was functional, 
we transfected the parental TC71 Ewing’s sarcoma cell line, which endogenously expresses 
PDGF-B, with 50ng/ml of either the pdgf-b/PGL3 construct we generated or the PGL3 
control vector for 48 hours. The cells were lysed and the luciferase signal was measured 
and quantified to analyze the pdgf-b promoter activity. We found that the pdgf-b promoter 
was activated and our pdgf-b/pGL3 construct was indeed functional (Figure A1). 
 
 
Figure A1. The pdgf-b/pGL3 construct is functional.  Luciferase assay. The TC71 Ewing’s 
sarcoma parental cell line from which we generated the VEGF165-inhibited TC/siVEGF7-1 cell line, 
endogenously expresses both SDF-1α and PDGF-B compared to TC/siVEGF7-1. We transfected the 
TC71 cells with 50 ng/mL of either the pdgf-b/ pGL3 construct or the pGL3 control vector for 48 
hours. The cells were lysed and the promoter activity analyzed by measuring the total luciferase 
signal. The pdgf-b promoter is activated in TC71 Ewing’s sarcoma cells.  
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SDF-1α induces the phosphorylation of the ELK-1 transcription factor at serine 383 
with a peak at 30 minutes in TC/siVEGF7-1 cells  
The ELK-1 transcription factor is activated by phosphorylation at serine 383 (S383) 
(59, 71). To demonstrate that the recombinant human SDF-1α protein activated the ELK-1 
transcription factor, TC/siVEGF7-1 cells were plated in the absence of growth factors and 
supplements for 24 hours and treated with either the recombinant human SDF-1α or 9SDF-
1α inactive protein for 15, 30 or, 60 minutes. The cells were lysed and the nuclear versus 
cytoplasmic protein extracts were isolated. We performed western blot analysis for total 
and phosphorylated serine 383 ELK-1 (pELK-1-S383) using lamin B as a nuclear loading 
control. Both total and p-ELK-1-S383 were normalized to lamin B by densitometry and the 
ratio of phospho p-ELK-1-S383 to total ELK-1 was measured.  We found that SDF-1α 
phosphorylated the ELK-1 transcription factor at S383 with a peak at 30 minutes (Figure 
A2). These findings supported our previous observations that SDF-1α induced binding of 
ELK-1 to the pdgf-b promoter with a peak at 30 minutes (chapter 3).  
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Figure A2. The ELK-1 transcription factor is phosphorylayed at S383 in response to SDF-1α 
stimulation in TC/siVEGF7-1 cells. Western blot for pELK-1(S383). TC/siVEGF7-1 cells were 
plated in the absence of growth factors and supplements for 24 hours and then treated with 100 
ng/mL of  either  (A) the recombinant human SDF-1α protein or (B) the 9SDF-1α inactive protein 
for 15, 30 or, 60 minutes. The nuclear versus cytoplasmic extracts were isolated and western blot for 
total ELK-1, pELK-1-S383 and, lamin B was performed. Actin in panel (A) was used as a loading 
control to verify the efficiency of the nuclear versus cytoplasmic separation. Densitometry was 
performed on the bands and both total and p-ELK-1-S383 were normalized to lamin B. The 
numbers below both panels represent the ratio of normalized pELK-1-S383 relative to normalized 
total ELK-1 protein. SDF-1α induces the phosphorylation of ELK-1 at S383 with a peak at 30 
minutes post stimulation compared to 9SDF-1α.   
 
                                                                                                                                                                             
 
93
 
 
 
 
 
 
 
 
Chapter 9. 
Discussion and future directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                             
 
94
Discussion 
 
SDF-1α regulates PDGF-B by a transcriptional mechanism which involves the ELK-1 
transcription factor  
We previously demonstrated that inhibiting VEGF165 in TC71 tumor cells 
(TC/siVEGF7-1) resulted in smaller tumors with decreased vasculogenesis and infiltration of 
bone marrow cells (BMCs) to the tumor site (16, 23, 40). Intratumoral injections with an 
adenoviral vector containing the SDF-1α gene (Ad-SDF-1α) up-regulated the expression of 
SDF-1α, increased BM-derived pericytes surrounding the tumor vessels and, rescued tumor 
growth.  Because PDGF-B is involved in pericyte differentiation, we examined sections 
from the tumors treated with Ad-SDF-1α for the expression of PDGF-B and found that 
SDF-1α gene therapy increased PDGF-B mRNA levels as well as SDF-1α expression. In 
contrast, SDF-1α had no effect on VEGF165 (40). These findings suggested a correlation 
between SDF-1α, PDGF-B and the formation of pericytes from BMCs.  
Platelet derived growth factor B (PDGF-B), a member of the PDGF family of 
growth factors, is a mitogen for cells of mesenchymal origin such as fibroblasts and smooth 
muscle cells. When synthesized and secreted in its homodimer form, PDGF-BB binds to its 
tyrosine kinase receptor, PDGFR-β (49, 53). The expression of PDGF-B and PDGFR-β is 
usually restricted to a limited number of cell types in areas of vascular development. 
However, many cancers, including colorectal cancer, pancreatic cancer, glioma, and 
sarcoma, have been shown to over-express PDGF-B (53, 54, 66). The mechanisms by 
which PDGF-B is up-regulated in areas of vascular remodeling remain unclear.  
                                                                                                                                                                             
 
95
PDGF-B expression can be regulated by several mechanisms, including 
transcriptional regulation (60). Studies by Onimaru and colleagues in 2009 demonstrated 
that VEGFC can regulate vascular stabilization by controlling PDGF-B expression (67). In 
the current study, we are the first to demonstrate that SDF-1α regulates PDGF-B. We 
stained the tumor sections from the Ad-SDF-1α treated TC/siVEGF7-1 tumors and 
confirmed that SDF-1α up-regulated PDGF-B protein levels as well as mRNA levels 
(chapter 2). Furthermore, treating two different cell lines (TC/siVEGF7-1 and HEK293) with 
the recombinant human SDF-1α increased the expression of PDGF-B mRNA and protein 
levels in vitro. In contrast, an shRNA specific for SDF-1α down-regulated both SDF-1α and 
PDGF-B (chapter 2). We cloned the pdgf-b promoter into the pGL3 reporter vector and 
demonstrated that SDF-1α activated the pdgf-b promoter. These findings demonstrated that 
SDF-1α regulates PDGF-B via a transcriptional mechanism (chapter 3).  
SDF-1α or CXCL12 is an alpha chemokine that binds to the 7-transmembrane G-
protein coupled receptor CXCR4 (68, 72). Signaling through the SDF-1α/CXCR4 pathway 
initiates multiple downstream signaling pathways linked to transcription and expression 
through MEK1/2 and ERK1/2 for example. ERK can phosphorylate and activate other 
cellular proteins as well as translocate to the nucleus and phosphorylate and /or activate 
transcription factors (68). Although the JAK/STAT signaling pathway has also been shown 
to be activated in response to the SDF-1α/CXCR4 axis, the involvement of the STAT 
proteins in signaling in response to CXCR4 activation may depend on the cell type. Several 
studies have investigated the role of this pathway in hematopoietic cells; however, the 
effect of SDF-1α on the JAK/STAT pathway and its role in cell  signaling remain an area of 
investigation (28).   
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The binding of SDF-1α to CXCR4 induces phosphorylation of the mitogen-
activated protein kinases (MAPKs) p44 ERK-1 and p42 ERK-2, which subsequently 
initiates the phosphorylation of the nuclear transcription factor ELK-1 (64). The ELK-1 
nuclear transcription factor is a member of the 3 ternary complex factors (TCFs), a 
subfamily of the ETS-domain transcription factors. TCFs are involved in several biological 
processes and have been shown to be important in regulating angiogenesis and 
vasculogenesis (59, 62, 63, 73). A study by Kujoth and colleagues in 1998 demonstrated 
that binding of ETS family members is important for the function of the c-sis/PDGF-B 
TATA neighboring promoter sequence in K562 human erythroleukemia cells treated with 
12-O-tetradecanoylphorbol-13-acetate (60). We therefore investigated whether the ELK-1 
transcription factor binds to the pdgf-b promoter in response to SDF-1α stimulation.  
We identified potential ELK-1 binding sites both within the pdgf-b promoter region 
at the - 600bp and the transcription start site (TS) and, within the transcribed region at the 
+1 Kb site. We treated both TC/siVEGF7-1 and HEK293 cells with SDF-1α for 15, 30 or, 60 
minutes and performed chromatin immunoprecipitation (ChIP) on the samples. Real time 
PCR (q-PCR) showed that the ELK-1 transcription factor bound with high affinity to the 
pdgf-b promoter at the – 600 bp site with a peak at 30 minutes post SDF-1α stimulation. In 
contrast, ELK-1 did not bind with high affinity to the TS site in either cell line. We 
observed a large deviation in binding of ELK-1 at the TS site as indicated by the error bars 
in the graphs. We hypothesize that this deviation is a result of a cycling between the bound 
and unbound state of the transcription factor, attributed to the low affinity of ELK-1 for the 
TS site. The ELK-1 transcription factor recognizes the binding site, but is quickly released. 
These findings suggest that binding of ELK-1 at the TS site is not critical for the activation 
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of the pdgf-b promoter. As for the + 1 Kb site, we found that while ELK-1 bound to this site 
in the TC/siVEGF7-1 cells, it did not bind in the HEK293 cells. Further studies are needed to 
determine the role of this site in the transcription of PDGF-B in the TC/siVEGF7-1 cells.  
These observations, combined with our previous findings that SDF-1α activated the 
2 kb pdgf-b promoter, suggested that binding of ELK-1 to the – 600 bp site within the pdgf-
b promoter is sufficient for promoter activation. However, while we demonstrated that 
ELK-1 is involved in the transcription of PDGF-B, it is difficult to conclude that ELK-1 
binding is absolutely essential in this process and whether this transcription factor binds as 
a single moiety or within a transcriptional protein complex. Members of the ETS family of 
transcription factors have been shown to bind co-regulator proteins such as the serum 
response factor (SRF) protein (62). Additional studies would require inhibiting ELK-1 from 
binding to the – 600 bp site by directly mutating the ELK-1 – 600 bp binding site within the 
pdgf-b promoter for example. An immunoprecipitation assay could also be performed to 
test whether ELK-1 is binding to the promoter site as a protein complex with the SRF.  
The SDF-1α/PDGF-B pathway plays a critical role in BM-derived pericyte 
differentiation during vasculogenesis of Ewing’s sarcoma 
 As mentioned above, previous findings from our group demonstrated that treating 
TC/siVEGF7-1 tumors with Ad-SDF-1α up-regulated PDGF-B mRNA levels while also 
restoring vasculogenesis with infiltration of BMCs into the tumor site to a perivascular area 
where they differentiated into pericytes (40). These observations suggested an association 
between SDF-1α, PDGF-B and the formation of pericytes from BMCs. In chapters 2 and 3, 
we confirmed that SDF-1α regulated PDGF-B mRNA and protein expression both in vitro 
and in vivo. We therefore hypothesized that the increased BM-derived pericyte coverage 
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observed in the TC/siVEGF7-1 tumors after SDF-1α gene therapy was a result of the up-
regulation of PDGF-B by SDF-1α.  
PDGF-B and its receptor, PDGFR-β, are mainly expressed in the developing 
vasculature (51). PDGF-B is produced by endothelial cells and PDGFR-β is expressed by 
pericytes and vascular smooth muscle cells (49). PDGF-B and PDGFR-β have been shown 
to play a critical role in the process of pericyte maturation. Over expression of PDGF-B in 
colorectal and pancreatic cancer increased pericyte content (66) whereas lack of PDGFR-β 
signaling led to pericyte loss, which in turn resulted in endothelial cell changes and 
capillary dilation and rupture (51, 53). Furthermore, PDGFR-β+ pericyte progenitor cells 
(PPPs) have been shown to migrate to sites of tumor growth, where they differentiated into 
NG2+, desmin+, and α-SMA+ pericytes (57). In fact, studies by Gabriele Bergers and 
colleagues showed that HIF1-α, a direct effector of hypoxia, induced recruitment of BM-
derived myeloid cells, as well as endothelial and pericyte progenitor cells to promote neo-
vascularization in glioblastoma through increases in SDF-1α (39, 68).  
To determine whether the SDF-1α/PDGF-B pathway played a critical role in the 
process of pericyte maturation in vitro, we established an in vitro pericyte differentiation 
model and investigated the effect of SDF-1α on PDGFR-β+ BMCs collected from the hind 
femurs of mice. Fresh BMCs expressed the early pericyte marker PDGFR-β but, they did 
not express the mature pericyte markers, NG2 and desmin. Conditioned medium containing 
both SDF-1α and PDGF-B induced PDGFR-β+ BMCs to acquire a pericyte-like 
morphology and to express both NG2 and desmin, indicating pericyte differentiation. This 
effect was abolished when SDF-1α was inhibited and PDGF-B expression was decreased. 
Taken together, our data support the concept of an SDF-1α/PDGF-B pathway that plays a 
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critical role in the differentiation of BMCs into mature pericytes in vitro. We therefore 
anticipated that inhibiting SDF-1α in the Ewing’s sarcoma tumor microenvironment would 
also down-regulate PDGF-B expression and inhibit BMC differentiation into pericytes, 
with a subsequent negative impact on tumor growth and metastasis. 
Pericytes, also known as smooth muscle cells or mural cells, wrap around 
endothelial cells which together form the basement membrane of the vessel wall (42). 
Pericytes are recruited by PDGF-B-expressing endothelial cells to the sites of vessel 
remodeling, where they play a role in vascular stabilization, maturation, and survival (43, 
57). Since pericytes appear sparse and detached from the vessel wall in tumors (57), they 
have been neglected as a potential target for anti-vascular therapy. However, recent studies 
demonstrated that pericytes are important constituents of the tumor vessel wall (57). 
Depleting pericytes in a Lewis lung carcinoma tumor model using a DNA oligonucleotide 
aptamer (AX102) which selectively binds to PDGF-B resulted in regression of the tumor 
(58).  
We investigated the role of SDF-1α in neo-vascularization of Ewing’s sarcoma 
tumors; specifically, the role of the SDF-1α/PDGF-B pathway in the differentiation of 
BMCs into pericytes. We used the SDF-1α antagonist AMD 3100, a bicyclam molecule 
which specifically disrupts the SDF-1α/CXCR4 axis. This drug is currently used in the 
clinic in patients undergoing allogeneic transplantation due to its effectiveness in 
mobilizing BMCs from the BM into the peripheral blood while displaying low or no toxic 
side effects (69, 70). We performed a BMT from GFP+ mice into nude mice. one month 
following engraftment, the mice were subcutaneously injected with either TC71 or A4573 
Ewing’s sarcoma cells. Once the tumors became palpable, the mice received daily 
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subcutaneous injections of either PBS or 5 mg/kg AMD 3100 for the duration of the 
experiment. The experiment was terminated once the maximum tumor side measurement in 
the PBS control group reached the maximum size of 2 centimeters (~ 3 weeks). The tumors 
were resected and tumor sections were analyzed by immunohistochemistry (IHC).   
We analyzed the effect of AMD 3100 on tumor blood vessel morphology and 
perfusion in both the TC71 and A4573 Ewing’s tumors. Prior to sacrificing the mice, we 
intravenously (i.v.) injected them with the Hoechst33342 dye in order to label perfused 
vessels. Tumor sections were stained for the CD31 endothelial cell marker as well to label 
the blood vessels. We found that inhibiting SDF-1α signaling in both TC71 and A4573 
tumors resulted in smaller vessels with smaller lumens and decreased vessel perfusion 
compared to PBS. Although our findings cannot determine the effect of SDF-1α on vessel 
functionality, they do support the conclusion that the vessels in the AMD 3100 group are 
less efficient in delivering blood to the tumor mass compared to the PBS control group. To 
further validate these observations, we performed TUNEL staining on the tumor sections 
and showed that AMD 3100 treatment increased tumor apoptosis. Taken together, our 
findings demonstrate that SDF-1α signaling plays a critical role in tumor vascular 
development. 
To further characterize the role of SDF-1α signaling in the process of Ewing’s 
sarcoma tumor vascular development, specifically in the differentiation of BMCs into 
pericytes during vasculogenesis, we stained the tumor sections for GFP to label BMCs, 
CD31 to label tumor vasculature and, desmin and NG2 to detect mature pericytes. We 
found that AMD 3100 did not inhibit migration of BMCs to the tumor site. However, the 
distribution of the BMCs relative to the tumor vasculature was affected. The BMCs 
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preferentially differentiated into endothelial cells and did not form thick perivascular layers 
surrounding the tumor vessels like the BMCs in the PBS control group. Furthermore, the 
infiltrating GFP+ BMC population did not differentiate into desmin and NG2 positive 
pericytes.  
Taking into consideration our previous studies which demonstrated that VEGF165 is 
over expressed in both TC71 and A4573 Ewing’s sarcoma tumors and that this growth 
factor is the chemotactic stimulus for BMC migration to the tumor site (16, 23); we 
concluded that the infiltration of BMCs into the AMD 3100- treated mice could be 
attributed to the expression of VEGF165 in the tumor microenvironment. Our previous 
studies showed that introducing SDF-1α into VEGF165-inhibited tumors did not affect the 
expression of VEGF165 (40). These observations suggest that VEGF165 is up-stream of SDF-
1α in the signaling cascade. Therefore, we anticipate that inhibiting SDF-1α signaling 
should have no effect on VEGF165 expression in both TC71 and A4573 tumors. To 
summarize, our findings demonstrated a critical role for SDF-1α signaling in the process of 
pericyte differentiation during vasculogenesis of Ewing’s sarcoma.  
We analyzed the overall residual pericyte population in the AMD 3100 treated 
group by staining for CD31+ endothelial cells in combination with desmin and NG2 mature 
pericyte markers. We found that AMD 3100 decreased the overall number of pericytes 
compared to PBS within both TC71 and A4573 tumors. We attributed this decrease in 
pericyte number to the previous findings that inhibiting SDF-1α signaling inhibited BM-
derived pericyte differentiation. We characterized the few remaining pericytes as locally-
derived pericytes and not BM-derived as they were negative for GFP. These residual 
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pericytes remained in close proximity with the CD 31+ endothelial cell layer and could 
potentially function to support the remaining tumor vasculature.  
In chapters 2 and 3, we showed that SDF-1α regulated PDGF-B expression via a 
transcriptional mechanism and that the SDF-1α/PDGF-B pathway played a critical role in 
the differentiation of BMCs into pericytes in vitro. To demonstrate that SDF-1α induces the 
differentiation of BMCs into pericytes by regulating PDGF-B expression in the tumor 
microenvironment, we analyzed the effect of AMD 3100 on PDGF-B expression in both 
TC71 and A4573 tumors. We stained the tumor sections from the AMD 3100 treated 
tumors for PDGF-B expression and confirmed that inhibiting SDF-1α signaling in vivo, 
down-regulated PDGF-B. We concluded that the loss in BM-derived pericyte 
differentiation observed in the AMD 3100-treated mice was an effect of the down-
regulation in PDGF-B expression. These findings helped further validate our hypothesis 
that the SDF-1α/PDGF-B pathway plays a critical role in BM-derived pericyte 
differentiation during vasculogenesis of Ewing’s sarcoma.  
A possible alternative for the decrease in pericyte content observed in the AMD 
3100-treated mice could be argued. The loss of pericyes could be attributed to the negative 
impact of AMD 3100 directly on the blood vessels themselves. Pericytes are defined as the 
supportive cell layer which surrounds the endothelial cells and maintains the vessel wall 
(42). Therefore, if the endothelial cell layer is not there to begin with, then that could 
explain the decrease in BM-derived pericytes. However, several studies including a study 
by Donald McDonald and colleagues in 2007, demonstrated that inhibiting PDGF-B in 
Lewis lung carcinomas led to pericyte loss and reduced tumor vascularity. More 
specifically, they showed that the tumor vascular reduction was in fact secondary to 
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pericyte loss and suggested that the pericyte layer is necessary for the endothelial cells to 
form the vessel wall (58). These observations validate our findings that the SDF-1α/PDGF-
B pathway plays a critical role in BM-derived pericyte differentiation.  
AMD 3100 as an anti-vascular therapeutic agent  
Until recently, pericytes have been considered abnormal and dysfunctional in 
tumors and therefore, they have been neglected as potential targets for anti-vascular therapy 
(42). However, recent studies in Lewis lung carcinomas by Donald McDonald and 
colleagues (58) and in pancreatic islet cancers by Gabriele Bergers and colleagues (42, 48) 
have demonstrated that although pericytes are present in a smaller number within tumors, 
targeting pericytes in addition to endothelial cells, resulted in more efficient reduction in 
tumor vasculature than targeting one or the other alone (48). In the current study, we 
showed that inhibiting SDF-1α signaling down-regulated PDGF-B expression and 
simultaneously inhibited differentiation of BMCs into pericytes which reduced the tumor 
vasculature (chapters 5 and 6).  
We also investigated the effect of inhibiting BM-derived pericyte differentiation on 
tumor growth in both TC71 and A4573 Ewing’s sarcoma tumors. We performed a BMT as 
previously described (Figure 1). Following engraftment, we subcutaneously injected the 
mice with either TC71 or A4573 Ewing’s cells. Once the tumors became palpable, we 
measured the tumor volume and started daily subcutaneous injections of either PBS or 
5mg/kg AMD 3100. We recorded the tumor volumes twice weekly for the duration of the 
experiment. The experiment was terminated once the longest tumor side measurement 
within the PBS control group reached the maximum size of 2 centimeters (3 weeks post 
tumor cell inoculation). We found that even though AMD 3100 had reduced the tumor 
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vasculature and resulted with a trend towards smaller tumor volumes, this difference was 
not statistically significant. We then investigated whether targeting BM-derived pericytes 
stabilized tumor growth and increased overall mice survival. We performed a survival study 
where we repeated the experimental design as previously described. This time however, we 
sacrificed the mice individually once their longest tumor side measurement reached the 
maximum size of 2 centimeters. We found that AMD 3100 did not statistically prolong 
survival of the tumor-bearing mice. These findings demonstrated that AMD 3100 had no 
therapeutic effect when administered as a single anti-vascular agent.  
To help interpret our findings, we concluded that inhibiting BM-derived pericyte 
differentiation specifically was not sufficient to impact overall tumor growth. Even though 
pericyte content was decreased, we still detected a population of residual locally-derived 
pericytes. Surprisingly, normal vessels in mice have been shown to tolerate substantial 
decreases in pericyte density. A study by Abramsson and colleagues in 2003, showed that 
only a reduction higher than 90% was embryonic lethal (42, 55). These observations 
suggest that even such a small number of residual pericytes, such as the ones observed in 
the AMD 3100-treated mice, could be functional and sufficient for vessel stability and 
endothelial-cell survival.  
Targeting pericytes alone is less efficient than targeting both endothelial cells and 
pericytes individually (42). Similar to our findings, Donald McDonald’s study in 2007 
where the aptamer AX102 was used to inhibit PDGF-B in Lewis lung carcinomas and 
pancreatic islet cancers, loss of pericytes resulted in reduced tumor vasculature but did not 
retard tumor growth (58). In contrast, a study in pancreatic islet cancers by Gabriel Bergers 
and colleagues in 2003 showed that targeting both endothelial cells and pericytes using 
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anti-VEGF receptors and anti- PDGF receptors in combination was more effective at 
reducing tumor growth and promised a more effective therapeutic approach (48). To further 
validate our findings, pericytes in general are less abundant within tumors. In fact, 
glioblastomas have been shown to contain a substantial number of vessels that are not 
covered by pericytes. In these tumors, the vessels are more dependent on VEGF signaling 
for endothelial cell survival. Therefore, targeting VEGF in this tumor type is more efficient 
at reducing both the tumor vasculature and growth (42, 74). Therefore, we propose to 
investigate the effect of AMD 3100 on tumor growth when administered in combination 
with another anti-VEGF agent and anticipate a more efficient vascular reduction and tumor 
growth inhibition.  
Overall, our study demonstrated and suggested a potential mechanism by which 
SDF-1α regulates the expression of PDGF-B in the tumor microenvironment during tumor 
vascular remodeling. Specifically, our findings elucidate the critical role of the SDF-
1α/PDGF-B axis in the differentiation process of BM-derived pericytes which supports 
vasculogenesis of Ewing’s sarcoma. Taking into consideration that most solid tumors rely 
on an extensive vascular network for their survival and growth and for metastasis to distant 
organs (6), our study becomes significant and promising not only in targeting Ewing’s 
sarcoma but other solid tumors as well. A tumor vascular system is comparable to a subway 
system necessary for the delivery of basic resources, such as oxygen and nutrients, to the 
different “zip codes” in a city. We anticipate that targeting the vascular wall by targeting 
both endothelial cells and pericytes would induce the vessel wall to collapse and therefore 
inhibit tumor growth. 
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Most anti-vascular agents, including those used in the treatment of Ewing’s 
sarcoma, target VEGF as the key regulator of vascular remodeling (75, 76). However, 
several studies, including our own, have shown that SDF-1α expression can be induced in 
the tumor microenvironment and can play a role in tumor neo-vascularization (39, 40). We 
therefore speculate that SDF-1α could potentially confer the tumor with an alternate 
pathway for vascular remodeling in a VEGF-independent manner. We propose that in the 
absence of VEGF, BMCs can still migrate to the tumor site in response to SDF-1α where 
they can participate in tumor neo-vascularization and therefore circumvent the effect of the 
various anti-VEGF agents currently used in the clinic. Our current study supports these 
speculations and emphasizes the importance of identifying new growth factors and 
signaling pathways such as the SDF-1α/PDGF-B axis as targets for anti-vascular therapy. 
Our findings also predict a promising effect for AMD 3100 (69, 70) if used in combination 
with other drugs to target the vasculature in patients with solid tumors.  
Understanding the interaction between the tumor and its host environment is 
essential in establishing new targeted therapies. However, it is important to remember that 
the tumor mass, as well as the pathways and growth factors its triggers, are heterogeneous. 
Therefore, uncovering these various signaling pathways and their implications in tumor 
survival will allow us to engineer new combinational therapies, such as combining anti-
VEGF and anti-SDF-1α (Avastin and AMD 3100) for example, to target both local 
angiogenesis and vasculogenesis and more efficiently inhibit tumor growth and increase 
patient survival.  
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Figure 22. Summary. The tumor and its cell constituents form a heterogeneous microenvironment 
where different signaling pathways and growth factors such as VEGF165, SDF-1α and, PDGF-B are 
induced. These growth factors play a critical role in promoting both local angiogenesis and 
vasculogenesis to support tumor neo-vascularization, growth, survival and, invasion. In our current 
study, we demonstrate that SDF-1α is produced in the tumor microenvironment, acts as a 
chemotactic factor for BMCs and, induces the expression and secretion of PDGF-BB. PDGF-BB 
can then bind to its receptor, PDGFR-β, expressed on the surface of infiltrating BMCs and induce 
their differentiation into mature pericytes. These findings demonstrate the importance of the tumor 
microenvironment in supporting tumor growth and the need to better understand the signaling 
pathways that govern tumor survival and progression in order to devise new therapeutic approaches.  
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Conclusion 
 SDF-1α regulates the expression of PDGF-B via a transcriptional mechanism which 
involves binding of the ELK-1 transcription factor to the pdgf-b promoter. This SDF-
1α/PDGF-B pathway plays a critical role in the differentiation of BMCs into pericytes 
during vasculogenesis of Ewing’s sarcoma.  
We demonstrated: 
1. SDF-1α regulates the expression of PDGF-B in vitro and in vivo 
We treated TC/siVEGF7-1 tumors in which VEGF165 has been down-regulated, with Ad-
SDF-1 and showed that it up-regulated PDGF-B mRNA and protein levels. In vitro, we 
treated both the TC/siVEGF7-1 and HEK293 cells with SDF-1α and showed it up-regulated 
PDGF-B mRNA and protein levels. In contrast, we down-regulated SDF-1α in 10T1/2 cells 
and showed that it down-regulated PDGF-B. 
2. SDF-1α regulates PDGF-B via a transcriptional mechanism  
We cloned the pdgf-b promoter into a reporter vector and showed that SDF-1α activated the 
pdgf-b promoter in both TC/siVEGF7-1 and HEK293 cells. 
3. SDF-1α induces binding of the ELK-1 transcription factor to the pdgf-b promoter 
We treated TC/siVEGF7-1 and HEK293 cells with SDF-1α and showed that SDF-1α 
induced binding of the ELK-1 transcription to the pdgf-b promoter with a peak at 30 
minutes post-stimulation.  
4. The SDF-1α/PDGF-B pathway plays a critical role in the differentiation of BMCs 
into pericytes in vitro 
We showed that BMCs collected from the hind femurs of mice differentiated into mature 
pericytes which express desmin and NG2 in the presence of SDF-1α and PDGF-B. In 
                                                                                                                                                                             
 
109
contrast, we showed that down-regulating SDF-1α down-regulated PDGF-B and abolished 
differentiation of BMCs into pericytes.  
5. The SDF-1α/PDGF-B pathway plays a critical role in the differentiation of BMCs 
into pericytes during vasculogenesis of Ewing’s sarcoma 
We treated the TC71 and A4573 tumor-bearing mice with the SDF-1α antagonist AMD 
3100 and showed that AMD 3100 led to smaller vessels with smaller lumens, decreased 
microvessel density and increased tumor apoptosis. We also showed that AMD 3100 down-
regulated PDGF-B expression and decreased the differentiation of BMCs into pericytes.  
6. AMD 3100 treatment alone did not display a therapeutic advantage in the treatment 
of TC71 and A4573 Ewing’s sarcoma primary tumors 
We treated the TC71 and A4573 tumor-bearing mice with the SDF-1α antagonist AMD 
3100 and showed that while AMD 3100 affected the tumor vascular density and 
morphology, it did not statistically decrease the overall tumor volume or increase the 
survival of tumor-bearing mice when administered as a single agent in both the TC71 or 
A4573 Ewing’s sarcoma primary tumors.  
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Future directions 
 
Investigate the therapeutic effect of AMD 3100 on Ewing’s sarcoma metastasis  
The role of SDF-1α as a chemotactic gradient for CXCR4+ cells and the implication 
of the SDF-1α/CXCR4 axis in tumor metastasis has been extensively described (77, 78). 
For example, recent studies showed that cancer cells which express CXCR4 home to the 
bone in a manner similar to the homing and retention of hematopoietic stem cells within the 
bone in response to SDF-1α gradients (79-81). Ewing’s sarcoma, a member of the Ewing’s 
sarcoma family of tumors (ESFT), is the second most common pediatric bone tumor after 
osteosarcoma (1, 2). Ewing’s sarcoma tumors display an aggressive behavior with a 
tendency towards recurrence following resection and are highly metastatic to the lungs 
(50%), bone (25%) and bone marrow (20%) (1-3). Despite a survival of about 65 – 75% in 
non-metastatic Ewing’s sarcoma patients, patients with recurrent disease or metastasis at 
the time of diagnosis, still have only about 20 – 25% overall survival (5). The need for 
improvement in therapy for patients with Ewing’ sarcoma is evident. The SDF-1α 
antagonist, AMD 3100 specifically disrupts the SDF-1α/CXCR4 axis and is currently used 
in the clinic in patients undergoing allogeneic transplantation due to its effectiveness in 
mobilizing BMCs from the BM into the peripheral blood while displaying low or no toxic 
side effects (69, 70). We propose that the SDF-1α/CXCR4 axis plays a role in Ewing’s 
sarcoma metastasis and therefore, investigating the effect of AMD 3100 as a therapeutic 
approach for the treatment of the metastatic disease in a mouse model is well merited.  
The TC71-PM4 Ewing’s cell line is a highly metastatic cell line which was 
generated from the TC71 parental cell line by repeated cycling through the lungs as 
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previously described (82). Nude mice will receive daily subcutaneous injections of either 
PBS or 5mg/kg AMD 3100 starting 3 days prior to them receiving an intravenous injection 
(i.v.) of the PM4 cells and, daily thereafter for the duration of the experiment. The 
experiment will be terminated 3-4 weeks following tumor cell inoculation and treatment. 
The mice will be sacrificed and the lungs resected and analyzed for micrometastasis. We 
anticipate that inhibiting the SDF-1α/CXCR4 axis using AMD 3100 should decrease the 
occurrence of PM4 lung metastasis in mice.  
Investigate the possibility of a BM pre-metastatic niche in the lungs which could 
function to support Ewing’s sarcoma metastasis post treatment with AMD 3100  
Metastasis is defined as the spread of tumors to distant sites away from the primary 
tumor and is responsible for the majority of cancer-related deaths (83). In 1889, Stephen 
Paget observed that circulating tumor cells did not randomly migrate to distant sites and 
metastasize, but rather, they would only form metastasis when the tumor cell, “seed” found 
the right microenvironment and factors to support its growth, the “congenial soil” (84). 
Several studies since have focused on better understanding the changes that take place 
within the distant metastatic “soil” in order to better understand tumor cell metastasis (80). 
David Kaplan and colleagues looked at the role of BMCs in the process of tumor 
metastasis. They demonstrated that VEGFR-1+ hematopoietic BM progenitor cells (HPCs) 
play an essential role in tumor metastasis by initiating the pre-metastatic niche. The BM-
derived VEGFR-1+ cells were observed in the metastatic sites as early as 14 days after 
tumor implantation and prior to the arrival of the metastatic tumor cells. Antibodies specific 
to VEGFR-1 inhibited the formation of the pre-metastatic niches and prevented tumor 
metastasis. Furthermore, SDF-1α was highly expressed in the fully formed metastatic 
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niches which suggested that SDF-1α mediated the recruitment and adherence of the 
incoming CXCR4+ cells (80, 85).  
In our current study, we used the SDF-1α antagonist AMD 3100 due to its 
specificity in disrupting the SDF-1α/CXCR4 axis. This drug is currently used in the clinic 
in patients undergoing allogeneic transplantation due to its effectiveness in mobilizing 
BMCs from the BM into the peripheral blood while displaying low or no toxic side effects 
(69, 70). Although AMD 3100 inhibted BMCs from infiltrating and differentiating into 
pericytes within the Ewing’s sarcom tumors, we anticipate that AMD 3100 induces a high 
influx of BMCs from the BM into the circulation. Here, we propose investigating whether 
this influx of BMCs can promote the formation of a pre-metastatic niche which could 
subsequently increase the tumor metastasis incidence post AMD 3100 treatment. These 
studies are important and clinically relevant prior to using AMD 3100 as an anti-vascular 
therapy. For even if AMD 3100 could be beneficial as an anti-vascular approach for the 
treatment of primary tumors; it may in fact be detrimental and augment tumor invasiveness 
and metastasis and, thereby, negatively impact overall patient survival.     
A bone marrow transplant (BMT) from GFP+ transgenic mice into nude mice will 
be performed (Figure 1). Following a period of 1 month for engraftment, the mice will 
receive a subcutaneous injection of either TC71 or A4573 Ewing’s sarcoma tumors. Once 
the tumors become palpable, the mice will receive daily subcutaneous injections of either 
PBS or 5mg/kg AMD 3100 for a period of 3 weeks. Mice from each group will be 
sacrificed the day treatment is started and twice a week while treatment is being 
administered and the lungs collected and analyzed for the presence of GFP+ BMCs and 
micrometastasis. At the end of 3 weeks, all primary tumors will be surgically resected and 
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the mice allowed to recover. Mice from each group will continue to be sacrificed twice 
weekly post surgery and their lungs collected and analyzed for GFP+ BMCs and 
micrometastasis. 
We anticipate that as long as AMD 3100 is being administered, BMCs and 
CXCR4+ tumor cells should not be able to stick and adhere within the lungs in response to 
SDF-1α signaling specifically. However, it is possible that other angiogenic growth factors 
are being expressed in the lungs such as VEGF which could compensate for the loss in 
SDF-1α signaling and consequently allow the BMCs to form a pre-metastatic niche and 
promote metastasis via an SDF-1α-independent mechanism. On the other hand, SDF-1α 
inhibition by AMD 3100 is reversible; therefore, we anticipate that once we stop delivering 
the AMD 3100 drug, the mobilized BMCs should be able to stick, adhere and, form a pre-
metastatic niche which might increase the incidence of tumor metastasis to the lungs.  
Investigate the therapeutic effect of AMD 3100 in combination with DC101 anti-
VEGFR-2 in Ewing’s sarcoma  
  In the current study, we demonstrated that SDF-1α played a critical role in 
vasculogenesis of Ewing’s sarcoma; specifically, in the differentiation of BMCs into 
pericytes during tumor neo-vascularization. Treating tumor-bearing mice with the SDF-1α 
antagonist, AMD 3100, led to smaller vessels with smaller lumens, decreased vessel 
perfusion, and, increased tumor apoptosis (chapter 5); however, when we analyzed the 
therapeutic effect of AMD 3100 on the primary Ewing’s sarcoma tumors, we found that 
inhibiting SDF-1α did not statistically decrease overall tumor volume or increase the 
survival of the tumor-bearing mice (chapter 8). Our findings correlated with the 
observations made by Donald McDonald and colleagues in Lewis lung carcinomas and 
                                                                                                                                                                             
 
114
pancreatic islet cancers where they used the aptamer AX102 to inhibit PDGF-B and showed 
that although the tumor vasculature was reduced, it did not retard the tumor growth (58). 
On the other hand, Gabriel Bergers and colleagues in 2003 showed that targeting both 
endothelial cells and pericytes by targeting both VEGF and PDGF receptors in 
combination, was more effective at reducing tumor growth and promised a more effective 
therapeutic approach (48). Furthermore, our lab demonstrated that vasculogeneis is 
essential for Ewing’s sarcoma and that VEGF165 is the chemotactic stimulus for BMC 
migration to the tumor site (10, 16, 23). We used DC101, a VEGF receptor 2 inhibiting 
antibody and showed that DC101 significantly inhibited the growth of Ewing’s sarcoma 
(25). All together, the essential roles of both SDF-1α and VEGF in tumor vascular 
development of Ewing’s sarcoma imply that administering AMD 3100 not as a single agent 
but rather, in combination with a compound such as DC101 in order to target VEGF may 
result in increased tumor growth inhibition. Findings from these studies could be used as 
preliminary insights into the potential of clinical trials involving combination studies using 
AMD 3100 with bevacizumab or avastin (anti-VEGF) for targeting both angiogenesis and 
vasculogenesis simultaneously and consequently result with a more effective anti-vascular 
approach for the treatment of this disease.  
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Chapter 10. 
Materials and Methods 
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Cell lines and culture 
We used the human Ewing’s sarcoma cell lines A4573, TC71 and, VEGF165 -
inhibited TC/siVEGF7-1 generated by stable transfection of VEGF165 siRNA into TC71. 
TC/siVEGF7-1 cells express all the VEGF isoforms except VEGF165 (24). Human 
embryonic kidney 293 (HEK293) cells and C3H/10T1/2 murine embryonic mesenchymal 
cells were purchased from ATCC (Manassas, VA; CRL-1573, CCL-226). TC/siVEGF7-1 
and HEK293 cells express low levels of endogenous SDF-1α and PDGF-B compared with 
C3H/10T1/2 cells. All cells were cultured in complete Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 
mM nonessential amino acids, 1 mM penicillin-streptomycin, and 2x vitamin solution 
(Gibco BRL, Grand Island, NY).  
Proteins and antibodies 
Recombinant human SDF-1α was purchased from R&D Systems (Minneapolis, 
MN; 350-NS-010/CF). The inactive 9SDF-1α recombinant protein used as a negative 
control was a generous gift from Dr. Qing Ma at The University of Texas MD Anderson 
Cancer Center. Rabbit polyclonal immunoglobulin (IgG) to human ELK-1, rabbit 
polyclonal IgG to mouse desmin and, chicken polyclonal IgG to GFP were purchased from 
Abcam (Cambridge, MA; ab28831, ab15-200, ab13970). ChromPure rabbit control IgG 
was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA; 011-000-
003). Rabbit polyclonal IgG to mouse PDGF-BB (N-30) and rabbit polyclonal IgG to 
mouse PDGFR-β (P-20) were purchased from Santa Cruz Biotechnology (CA; sc-127, sc-
339). Rabbit polyclonal IgG to mouse NG2 chondroitin sulfate proteoglycan was purchased 
from Millipore (Bedford, MA; AB5320). Rabbit polyclonal IgG to phsopho-ELK-1 (serine 
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383) and ELK-1 were purchased from Cell Signaling Technology (Danvers, MA; 9181, 
9182).  
q-PCR  
TC/siVEGF7-1 and HEK293 cells were cultured in vitro in the absence of growth factors 
and supplements for 8 hours and then treated with 100ng/mL of either the recombinant 
human SDF-1α protein or the inactive 9SDF-α inactive protein for 24 hours. RNA was 
collected by the TRIzol method (Invitrogen, Grand Island, NY). Briefly, the medium was 
removed and the cells were treated with 1mL of TRIzol for 5 minutes at room temperature 
(RT). The cells were collected, and 200µL of chloroform (Fisher Scientific, Pittsburgh, PA) 
was added for 3 minutes at RT. The mixture was then centrifuged in the Centrifuge 5415-R 
(Eppendorf, Westbury, NY) for 15 minutes at 4oC. The upper clear phase was collected, 
and 500µL of isopropanol (Fisher Scientific) was added for 10 minutes at RT. The solution 
was centrifuged for 10 minutes at 4oC, and the pellet was re-suspended and washed 2 times 
with 75% ethanol for 5 minutes at 4oC. The pellet was air-dried, re-suspended in 30µL of 
nuclease-free water (Promega, Sunnyvale, CA), and incubated at 65oC for 5 minutes. cDNA 
was synthesized using a reverse-transcription system (Promega). Real-time quantitative 
reverse-transcription polymerase chain reaction (q-PCR) was performed using iQ-SYBR 
Green Supermix with the iCycler iQ (Bio-Rad Laboratories, Hercules, CA).  
ELISA 
TC/siVEGF7-1 and HEK293 cells were cultured in vitro in the absence of growth factors 
and supplements for 8 hours and then treated with 100ng/mL of either SDF-1α or the 
inactive 9SDF-1α protein for 36 hours. The supernatant was collected and concentrated 
using Amicon Ultra-15, PLGC Ultracel-PL Membrane, 10 kDa (Millipore) by centrifuging 
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at 2500rpm for 30 minutes at 4oC in the Centrifuge 5804R (Eppendorf). PDGF-B protein 
levels were measured by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, 
Minneapolis, MN; MBB00) according to the manufacturer’s protocol.  
ShRNA knockdown of SDF-1α in C3H/10T1/2 cells 
SDF-1 shRNA Plasmid (m) (sh-SDF-1) and Control shRNA Plasmid-A (sh-control) were 
purchased from Santa Cruz Biotechnology (sc-39368-SH, sc-108060). C3H/10T1/2 
(10T1/2) cells were cultured in vitro and transfected with 1 µg of either sh-SDF-1 or sh-
control using FuGENE 6 (Roche Applied Science, Indianapolis, IN) according to the 
manufacturer’s directions. At 48 hours after transfection, the medium was replaced with 
fresh DMEM and the cells were cultured under puromycin selection (2 µg/mL) (InvivoGen, 
San Diego, CA). RNA was isolated using the TRIzol method, and cDNA was synthesized 
using a reverse-transcription system (Promega). Down-regulation of SDF-1α was 
confirmed by q-PCR.  
pdgf-b promoter cloning 
DNA was isolated from TC71 Ewing’s sarcoma cells. The 2-kb pdgf-b promoter DNA 
fragment was isolated by PCR. Briefly, primers were designed and synthesized using 
Integrated DNA Technologies (IDT). All sequences are available upon request. The PCR 
product was run on a 1% agarose gel, and the 2-kb pdgf-b promoter DNA fragment was 
isolated and purified using the QIAquick Gel Extraction Kit (QIAGEN, Valencia, CA; 
28704). The purified sequence was ligated into the pCR2.1-TOPO expression vector using 
the TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA; K4560-01). The vector was isolated 
and purified with the QIAprep Spin Miniprep Kit (QIAGEN; 27104) according to the 
manufacturer’s directions, and the DNA sequence was verified by SeqWright DNA 
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Technology Services (Houston, TX). The2 kb pdgf-b promoter DNA fragment was then 
isolated and cloned into the pGL3-Basic luciferase reporter vector (Promega BioSciences, 
San Luis Obispo, CA; E1751). The pdgf-b/pGL3 reporter vector sequence was verified by 
SeqWright DNA Technology Services. To test the functionality of the pdgf-b/pGL3 
construct, we used 50ng of the construct to transfect TC71 cells and the pdgf-b promoter 
activity was tested by measuring the luciferase signal.  
Dual-luciferase reporter assay 
We used 50 ng of either the pdgf-b/pGL3 reporter construct or the pGL3-Control vector 
(Promega BioSciences; E1761) to transfect TC/siVEGF7-1 and HEK293 cells using 
FuGENE 6 (Roche Applied Science) according to the manufacturer’s directions. Beginning 
48 hours after transfection, the cells were cultured in the absence of growth factors and 
supplements for 24hours and then treated with 100 ng/mL of either the recombinant SDF-
1α or the inactive 9SDF-1α protein for 8hours. The cells were lysed and the luciferase 
signal measured using the Dual-Luciferase Reporter Assay System (Promega BioSciences; 
E1910) according to the manufacturer’s instructions.  
Western blot analysis 
TC/siVEGF7-1 cells were cultured in the absence of growth factors and supplements for 24 
hours and then treated with 100 ng/mL of either the recombinant human SDF-1α or 9SDF-
1α inactive proteins for 15, 30 or, 60 minutes. The cells were lysed and the nuclear versus 
cytoplasmic extracts were isolated according to the manufacturers instructions (Active 
Motif, Carlsbad, CA; 40010). Protein concentration was measured by the Bradford protein 
assay. 50µg of protein was mixed with (2x) SDS loading dye, boiled at 100oC for 5 minutes 
and, loaded on a 10% acrylamide gel for 3 hours at 95 volts. The proteins were then 
                                                                                                                                                                             
 
120
transferred onto a nitrocellulose membrane at 95 volts for 1 hour at RT. The gel was 
discarded and the membrane collected, blocked with 5% bovine serum albumin (BSA) for 1 
hour at RT and probed for either phospho-ELK-1 S383 or total ELK-diluted 1:500 in BSA 
blocking solution O/N at 4oC. The membrane was washed 3 times for 10 minutes in 1x 
TBST and probed with the ECL anti-rabbit IgG horseradish peroxidase-linked whole 
antibody (GE Healthcare, Little Chalfont Buckinghamshire, UK; NA934V) at 1:1500 in 
blocking solution for 1 hour.  The membrane was washed 3 times for 10 minutes with 1x 
TBST and exposed with the ECL Western Blotting Analysis System (RPN2109) for 2 
minutes at RT.  
ChIP assay 
Potential ELK-1 binding sites within the 2-kb pdgf-b promoter region were identified using 
the GeneRegulation.com MATCH software. 2 sites at -600bp and at the transcription start 
site (TS) which scored > 85% were analyzed by chromatin immunoprecipitation (ChIP) 
(Millipore) according to the manufacturer’s instructions. Briefly, TC/siVEGF7-1 and 
HEK293 cells were cultured in the absence of growth factors and supplements for 24 hours 
and then treated with 100 ng/mL recombinant human SDF-1α for 15, 30, or 60 minutes. 
The cells were collected and the proteins cross-linked to the DNA by incubating in 36% 
formaldehyde for 10 minutes at RT. The cells were sonicated and the DNA sheered using 
the Sonicator 3000 (Misonix, Farmingdale, NY) to produce fragments of 400- 800 bp. The 
lysates were pre-cleared with protein A/G agarose for 2 hours at 4oC and incubated with the 
anti-ELK-1 rabbit polyclonal antibody (Abcam) O/N at 4oC. The ELK-1/DNA/Ab complex 
was immunoprecipitated, isolated, and washed. Cros- linking was reversed with 5% NaCl at 
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Target Forward primer Reverse primer
Human PDGF-B                            TGCTGTTGAGGTGGTGTAGATGGT           AGTCGTGGCTGGGTTGGAATATGA
Human pdgf-b promoter                TGTCCGGTGGAAGAGGGTTTTT                 CTCCCGGCTGCAGGAGGAGA
Human ElK-1 (-600bp)                 GGAGATAGTAAACAGCAGGGTGACTGACGG       CTCCTAGCTGGTTGCCTGGCACAAC
binding site
Human ELK-1 (TS)                      CCAGAAGAGGAAAGGCTGTCTCCACCCAC       CTGCAGGAGGAGAAGTTGCCACCCTTTC
binding site
Human ELK-1 (+1Kb)                  GGAGTCGGCATGAATCGCTGCTGG              CAACTCACCTCGGCGCTGACCAGA C
binding site
Mouse SDF-1α CTTCATCCCCATTCTCCTCA              GACTCTGCTCTGGTGGAAGG
Mouse PDGF-B                             AAAGACACCTTCTTGGAGGGA             ATTAAGGTGGCGCGATAGGTCCTT
RT human PDGF-B                      CTTGCACACTTCCCCATCTT                     CTTGGGGATCTTTTCCCTTC
RT mouse SDF-1α CCAAACTGTGCCCTTCAGAT                    TGGGCTGTTGTGCTTACTTG
RT mouse PDGF-B                       GGCCACACACCTTCTCTGAT                    AAATGAACCGGAAGTGAACG
65oC O/N.  The DNA was isolated using the QIAquick PCR Purification Kit (Qiagen). We 
confirmed binding of ELK-1 by q-PCR.  
Primer sequences 
Primers for the human pdgf-b promoter and for human PDGF-B were designed and 
synthesized using Integrated DNA Technologies (IDT, Coralville, IA). Primers for human 
ELK-1 binding sites, for mouse SDF-1α and PDGF-B, and, for real time (q-PCR) were 
synthesized using Sigma-Genosys.com. Please refer to table 1 for primer sequences.  
Table 1. Forward and reverse primers. 
In vitro pericyte differentiation model 
Whole BMCs were isolated from nude mice by flushing their hind femurs with sterile PBS. 
Fresh BMCs were analyzed for PDGFR-β, desmin, and NG2 expression. Briefly, the cells 
were collected and then cytospun onto glass slides by centrifuging at 30 rpm for 2mins at 
RT in the Shandon Cytospin 2 centrifuge (Shandon Southern Products, Astmore, United 
                                                                                                                                                                             
 
122
Kingdom). To establish an in vitro pericyte differentiation model, we collected BMCs and 
cultured the cells in a 2-well Culture-Slide (BD Biosciences, Woburn, MA; 354102) either 
in complete DMEM alone or in conditioned medium obtained from 10T1/2, sh-SDF-1-
10T1/2 or sh-control- 10T1/2 cells (previously generated). Supernatant from the 
corresponding cells was collected, spun down at 1200 rpm for 5 minutes at 4oC in the 
Centrifuge 5804R (Eppendorf) to remove any debris or floating cells, and added to the 
freshly collected BMCs.  BMCs were kept in culture for 2 weeks and stained for the 
expression of PDGFR-β, desmin, and NG2 pericyte markers.  
2-well chamber immunocytochemistry staining 
BMCs were collected and cultured as previously described. The cells were fixed with cold 
acetone for 10 minutes, washed with PBS 3 times for 3 minutes, and incubated with 
blocking solution (4% normal fish serum in PBS) for 20 minutes at RT. Anti-PDGFR-β, 
anti-desmin, or anti-NG2 (1:600) in 4% blocking solution was added to the slides O/N at 
4oC. The slides were washed with PBS 3 times for 3 minutes and incubated in blocking 
solution for 10 minutes at RT. Alexa Fluor-594 secondary (Molecular Probes, Eugene, OR; 
1:1000 in blocking solution) was added for 1hour at RT, and the slides were washed with 
PBS 3 times for 3 minutes. Nuclei were stained with Hoechst 33342 dye (Molecular 
Probes; 1:10,000 in PBS) for 1 minute and the slides were washed with PBS 3 times for 3 
minutes. Images were captured using a Zeiss Axioplan fluorescence microscope (Carl Zeiss 
MicroImaging, Thornwood, NY) equipped with a 100-W Hg lamp and narrow bandpass 
excitation filters. Images were obtained using a cooled charge-coupled device Hamamatsu 
C5810 camera (Hamamatsu Photonics, Bridgewater, NJ).  
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Statistical analysis 
We used STATISTICA 6.0, Anova on-way software to analyze all the q-PCR, ELISA and 
ChIP results. For ChIP, the sample values minus the control values were used in one-way 
analysis of variance, with post hoc analysis using the Fisher least significant difference to 
determine significant differences. For the animal studies and quantification data, we used 
the SimplePCI and the the Mann-Whitney 2-tailed U-test software. P < 0.05 was considered 
statistically significant. 
Animals 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee at The University of Texas M.D. Anderson Cancer Center.  GFP+ transgenic 
mice used as donor mice in our BMT experiments, were purchased from Jackson 
laboratories (Strain c57bl/6-tg (actb-egfp)1osb/j). BALB/cAnN nude mice were purchased 
at four to six weeks old from either the National Cancer Institute (strain 01B70) or Charles 
River (strain nu/nu 088). 
TC71 and A4573 Ewing’s sarcoma tumor models 
Nude mice were implanted subcutaneously with either TC71 (2 x 106 cells/0.2mLsterile 
PBS) or A4573 (6 x 106 total cells given as 2 separate injections of 3 x 106/0.2 mL sterile 
PBS at day 1 and day 3 following the one month period of engraftment) Ewing’s sarcoma 
cells. The cells were checked for mycoplasma prior to injection and used at passages three 
to seven. All injections were performed using a 30 gage needle and using a 1 cc disposable 
syringe. Tumors were resected once the longest tumor side measurement in the PBS control 
group reached 2 centimeters. Resected tumors were snap frozen in Optimal Cutting 
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Temperature (OCT) solution (Sakura Finetek USA, Torrance, CA) and stored at – 80oC for 
further analysis.  
SDF-1α gene therapy on TC/siVEGF7-1 Ewing’s sarcoma tumors 
TC/siVEGF7-1 cells were implanted subcutaneously on the ventral side of nude mice 
(4x106/mouse). 3 days post tumor cell inoculation, the mice received intratumoral injections 
of Ad-SDF-1α or Ad-control (2.53 x 108 pfu/50µL/administration/mouse). A total of 5 
injections were administered over a period of 3 weeks. On day 23 after tumor cell 
inoculation, all tumors were carefully excised, weighed, placed in OCT, snap-frozen in 
liquid nitrogen, and stored at – 80oC for further analysis (40).  
Bone marrow transplant model (BMT; Figure 1) 
Bone marrow cells (BMCs) were collected from GFP transgenic by removing the hind 
femurs of mice, cutting the bone ends with sterile scissors and, flushing the bone marrow 
with sterile PBS using a 10 mL sterile syringe and 30 gauge needle. BMCs were then 
pelleted and re-suspended in sterile PBS. Meanwhile, nude mice were subjected to whole 
body lethal irradiation (900 rad) using a Cesium irradiator (137Cs Mark 1 Irradiator; J. L. 
Shepherd & Associates, Glendale, CA) to eradicate the endogenous BMCs. We then 
rescued the irradiated mice by injecting them intravenously (i.v.) with the previously 
collected GFP+ BMCs. At least 1 x 106 GFP+ BMCs/ mouse are needed to ensure successful 
reconstitution. The mice were allowed to recover for a period of one month prior to tumor 
cell injection to ensure BMC engraftment. Transplant success was confirmed by collecting 
BMCs as previously described from at least three representative mice and tested for GFP 
expression by flow cytometry (BD FACSAria, BD Biosciences). A transplant was 
considered successful if at least 90% of BMCs were GFP+.  
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PDGF-B immunohistochemistry and microscopy  
Frozen Tumor sections were cut, fixed with cold acetone for 5 minutes, acetone/chloroform 
for 5 minutes and, cold acetone for another 5 minutes. The slides were washed with PBS 3 
times for 3 minutes and incubated with blocking solution (5% normal horse serum + 1% 
normal goat serum in PBS) for 20 minutes at RT.  PDGF-B rabbit polyclonal IgG diluted at 
1:100 in blocking solution was added to the slides O/N at 4oC. The slides were washed with 
PBS 3 times for 3 minutes and incubated with blocking solution for 10 minutes at RT. 
Biotinylated goat anti-rabbit IgG (Biocare Medical, Concord, CA; GR608H) was added for 
30 minutes at RT, and the slides were washed with PBS 3 times for 3 minutes. The slides 
were incubated with 4plus streptavidin horseradish peroxidase (HRP) (Biocare Medical; 
HP604H) for 30 minutes at RT and washed with PBS 3 times for 3 minutes with PBS.  3,3'-
Diaminobenzidine (DAB) (Research Genetics, Huntsville, AL) was added for 5-10 minutes, 
and the slides were washed with distilled water 3 times for 3 minutes. The slides were 
counterstained with Gill’s hematoxylin #3 (Sigma-Aldrich, St. Louis, MO; GHS316). 
Images were captured using a Nikon Microphot-FXA microscope (Nikon Instruments, 
Melville, NY).  
Hoechst perfusion assay 
Nude mice were injected with either TC71 or A4573 Ewing’s sarcoma cells as previously 
described. However, in order to label vessel perfusion, we performed intravenous (i.v.) 
injections of the Hoechst nuclear dye (Molecular Probes, Invitrogen, CA; 33342).  
1.2mg/0.1mL of the Hoechst33342 was intravenously (i.v.) injected 2 minutes prior to 
sacrificing the mice by cervical dislocation.  
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Primary antibody Dilution factor Company
Chicken anti- GFP                                           1: 800           Abcam, Cambridge, MA
Rabbit anti- mouse desmin 1: 400                        Abcam, Cambridge, MA
Rabbit anti- mouse NG2                                  1: 600              Millipore, Billerica, MA
Rat anti- mouse CD31                                     1:500           BD Biosciences, Franklin Lakes, NJ
Secondary antibody
Alexa Flour 488 (anti-rat/anti-rabbit)             1: 1000                       Molecular Probes, Eugene, OR
Alexa Flour 594 (anti-rabbit/anti-chicken)     1: 1000                       Molecular Probes, Eugene, OR
Fluorescent immunohistochemistry analysis (IHC) 
Tumor sections were fixed with cold acetone for 10 minutes, washed with PBS 3 times for 
3 minutes and incubated with blocking solution (4% fish serum in PBS) for 20 minutes at 
RT.  Primary IgGs were diluted in blocking solution and added to the slides O/N at 4oC 
(refer to table 2). The slides were washed with PBS 3 times for 3 minutes and incubated 
with blocking solution for 10 minutes at RT. All secondary IgGs were diluted 1:1000 in 
blocking solution and added to the slides for 1 hour at RT (refer to table 2). The slides were 
washed with PBS 3 times for 3 minutes, incubated with Hoechst33342 (nuclear stain) 
diluted 1:10,000 in PBS for 30 seconds and, washed with PBS 3 times for 3 minutes.  
Table 2. Immunohistochemistry primary and secondary antibodies.  
TUNEL staining and microscopy 
Frozen Tumor sections were cut and fixed with 4% paraformaldehyde in PBS 20 minutes at 
RT. The slides were washed with PBS 3 times for 3 minutes and distilled water 1 time for 3 
minutes then treated with proteinase K (20mg/mL) diluted 1:1000 in distilled water for 10 
minutes at RT. The slides were washed with distilled water 4 times for 1 minute, incubated 
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with 3% H2O2 in methanol for 12 minutes and, washed with distilled water 4 times for 1 
minute and with 1x TdT buffer in water for 2 minutes. The slides were then incubated with 
Terminal Transferase diluted 1:400 + Biotin 16dUTP diluted 1:200 in 1x TdT buffer O/N at 
4oC.  Next, the slides were washed with PBS 2 times for 5 minutes and distilled water 3 
times for 1 minute then incubated with 5% normal horse serum diluted in 2% bovine serum 
albumin in distilled water for 10 minutes at RT. The slides were washed with distilled water 
3 times for 1 minute and PBS 1 time for 1 minute then incubated with 4plus streptavidin 
horseradish peroxidase (HRP; Biocare Medical; HP604H) for 30 minutes at RT. The slides 
were washed with PBS 3 times for 3 minutes. 3,3'-Diaminobenzidine (DAB; Research 
Genetics, Huntsville, AL) was added for 3 minutes and the slides were washed with 
distilled water 3 times for 3 minutes. The slides were counterstained with Gill’s 
hematoxylin #3 (Sigma-Aldrich, St. Louis, MO; GHS316). Images were captured using a 
Nikon Microphot-FXA microscope (Nikon Instruments, Melville, NY).  
Microscopy  
Images were captured with a Zeiss Axioplan fluorescence microscope (Carl Zeiss, Inc., 
Thornwood, NY) equipped with a 100-W Hg lamp and narrow bandpass excitation filters 
and the representative pictures were obtained using a cooled charge-coupled device 
Hamamatsu C5810 camera (Hamamatsu Photonics, Bridgewater, NJ) with the Optimas 
imaging software (Media Cybernetics, Bethesda, MD).  
Immunohistochemistry quantification  
Five random fields at either 10x or 20 x-magnification were captured from each slide from 
both the PBS and the AMD 3100-trated groups. The total positive pixels for each marker 
were measured using the SimplePCI software (Hamamatsu, Sewickley, PA). We then 
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measured the mean pixel area of positive fluorescence for each of the protein of interests 
from each tumor section. For the pericyte differentiation studies, the ratio of desmin or NG2 
positive to GFP positive pixels was measured.  
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